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ABSTRACT 
Introduction: Spatial, temporal and racial patterns of cancer remain largely unexplained in 
the United States. Time trends of cancer incidence and mortality can be used to estimate 
the current cancer burden, anticipate clinical care needs, and suggest hypotheses regarding 
possible etiologic explanations for underlying trends. Methods: Using U.S. 1979-2003 
cancer incidence and 1969-2003 cancer mortality data, age-period-cohort and Joinpoint 
regression models were fit to summarize gender- and race-specific temporal trends for 
three broad cancer categories that include tobacco-related cancer, screen-detectable 
cancer, and cancer unrelated to tobacco and screening. Demographic patterns and time 
trends of non-Hodgkin’s lymphoma (NHL) incidence between Pennsylvania and the U.S. 
from 1985 to 2004 were compared. Using Idaho cancer incidence, 1990-2005, and arsenic 
levels in ground water, 1990-2005, spatial analysis was conducted to identify geographic 
patterns of cancer incidence and to evaluate the relationship between arsenic exposure in 
ground water and cancer incidence in Idaho. Results: Over the last three decades, tobacco-
related cancer incidence declined among men and increased among women. Screen-
detectable cancer incidence increased, more rapidly among men than women. For cancer 
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unrelated to tobacco and screening, incidence increased in every gender-and-race group. 
Though not identical, NHL incidence patterns, with substantial increases, were similar in 
the U.S. and Pennsylvania. NHL incidence was higher in Pennsylvania counties with a 
greater percentage of urban residents. Although spatial clustering was demonstrated in 
Idaho cancer incidence, no relationship was found between arsenic exposure in ground 
water and Idaho cancer incidence. Conclusion: NHL and other cancers unrelated to 
smoking or screening have increased in the U.S. in the past two decades in white and black 
men and women. Etiologic research should attempt to identify modifiable risk factors, 
including environmental exposures, responsible for the increasing incidence of NHL and 
cancer unrelated to tobacco and screening. The ecologic association observed in 
Pennsylvania between NHL incidence and urban residence may be relevant to NHL risk in 
the entire United States. Additional environmental and demographic information should be 
evaluated in order to clarify the arsenic-related cancer risk in Idaho counties where ground 
water has been found to contain higher levels of arsenic. Public Health Significance: Age, 
period and cohort modeling of cancer incidence and mortality provides important 
indications of current and future health care needs and also suggests hypotheses for future 
research. The results of this analysis provide health professionals, researchers, and policy-
makers with detailed information and an understandable overview of cancer patterns in 
the United States. Hypotheses should be generated about these unexplained patterns of 
cancer so that avoidable cancer risks can be identified that will decrease the cancer burden 
and associated requirements for health care.  
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1.0  INTRODUCTION 
With an estimated 559,650 deaths for the year 2007 in the United States (U.S.), cancer is the 
second leading cause of death in the U.S. and accounts for nearly one-quarter of national deaths, 
exceeded only by heart diseases (American Cancer Society, 2007b). In middle-aged Americans, 
cancer is the leading cause of death,  and, after accidents, the disease is also the leading cause of 
death in children (Davis et al., in press). Compared to 1950, cancer mortality decreased slightly 
in 2004 (193.9 per 100,000 in 1950 and 185.8 per 100,000 in 2004, adjusted to the U.S. 2000 
standard population), while mortality for other major chronic diseases including heart disease, 
cerebrovascular disease, and pneumonia/influenza decreased noticeably from 1950 to 2004 
(American Cancer Society, 2007c). American Cancer Society (ACS) estimates that almost 1.4 
million new cancer cases will be diagnosed in 2007. In addition, approximately one out of every 
two American men and one out of every three American women will be diagnosed with some 
form of cancer during their lifetime, with 77% of all cancers occurring in people aged 55 or older 
(American Cancer Society, 2007b). Although cancer is a complex and multiply caused disease, 
the National Cancer Institute (NCI) and the World Health Organization (WHO) advise that many 
cancer occurrences or cancer deaths can be prevented by improving access to screening and early 
treatment, promoting the adoption of healthier lifestyles and improved nutrition, and controlling, 
reducing or avoiding exposures to workplace and other environmental carcinogens (National 
Cancer Institute, 2005a; World Health Organization, 2007).  
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Descriptive epidemiologic studies are indispensable for characterizing the cancer burden 
and for evaluating cancer control strategies, such as tobacco cessation and screening policies. 
Annually the U.S. spends about $100 billion in direct treatment costs for cancer. Time trend 
analysis of overall and site-specific cancer rates in population-based surveillance systems can 
indicate how variations in cancer occurrence and cancer deaths are associated with age, time 
period and birth cohort.  Thus, programs to screen and treat cancers can be evaluated in terms of 
the time period when they were introduced and the birth cohorts that first adopted such programs. 
Cancer trend analysis can also assist policy makers in anticipating the demand for health care.  
Finally, the evaluation of cancer trends can prompt researchers to generate hypotheses about 
underlying factors that account for patterns of the disease. These analyses ultimately will lay the 
groundwork for etiologic studies on unexplained patterns of cancer and suggest opportunities for 
the private sector and government to formulate primary and secondary cancer prevention policies. 
 Using data from the Surveillance, Epidemiology, and End Results (SEER) Program of 
the U.S. National Cancer Institute, organized in terms of birth cohorts, time periods and age, we 
examined cancer incidence and mortality in three broad cancer categories: cancer related to 
tobacco smoking, cancer associated with screening technology, and all cancers excluded in the 
smoking and screening categories. We also focused on non-Hodgkin’s lymphoma (NHL), a  
once rare cancer that is now common whose incidence has been strikingly increasing (National 
Cancer Institute, 2007b). Additional NHL cancer incidence data was obtained from the 
Pennsylvania Cancer Registry (PCR). These data were used to estimate the spatial-temporal 
trends in Pennsylvania, to compare the patterns between Pennsylvania and the entire U.S., and to 
explore demographic and other potential exogenous explanations for these patterns. 
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Another area of interest is the causative relationship between arsenic exposure and cancer 
risks. Arsenic, a metalloid, is considered a human carcinogen for more than forty years, although 
its mechanism of action remains poorly characterized.  Populations exposed to arsenic from 
drinking water at levels of fifty parts per billion or higher have been found to face major public 
health risks (World Health Organization, 2001). By using a Geographic Information System 
framework, we evaluated the relationship between cancer incidence data from Cancer Data 
Registry of Idaho and arsenic data in ground water from the Idaho Department of Environment 
Quality. However, we were unable to evaluate the role of other potential carcinogenic exposures 
to this population. 
1.1 CANCER STATISTICS  
1.1.1 Cancer Data 
Studies on cancer statistics mainly use data from population-based cancer registries that code 
ascertained cancer cases according to the International Classification of Disease for Oncology 
(ICD-O) rules.(World Health Organization, 2000) Cancer data in the U.S. are usually provided 
by the SEER program of the NCI, (National Cancer Institute, 2005c). The SEER 9 registries 
have been collecting and reporting cancer incidence and survival data since 1973 for various 
parts of the U.S. In 1975, the SEER 9 registries have covered 9.5% of total U.S. population, 
including the states of Connecticut, Iowa, New Mexico, Utah, and Hawaii and the metropolitan 
areas of Detroit, San Francisco-Oakland, and Atlanta, and the 13-county of Seattle-Puget Sound 
(National Cancer Institute, 2005c). The current SSER system collects and reports cancer 
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incidence and survival data from 15 population-based central cancer registries that cover 26 
percent of the U.S. population. The U.S. racial/ethnic population coverage in SEER includes 23 
percent of African Americans, 40 percent of Hispanics, 42 percent of American Indians and 
Alaska Natives, 53 percent of Asians, and 70 percent of Native Hawaiian and other Pacific 
Islanders (United States Department of Health and Human Services (DHHS), 2006). State cancer 
registries have been also used to estimate cancer rates on a smaller scale. Since 1994, 
information from statewide cancer registries, the National Program of Cancer Registries (NPCR), 
has recently been combined with SEER data to provide nearly complete coverage of the U.S. 
population with respect to cancer incidence (Centers for Disease Control and Prevention, 2007). 
Age-adjusted and age-specific rates can each be used in the statistical analysis of cancer 
research. An age-adjusted rate, also known as an age-standardized rate (ASR), is a weighted 
average of the age-specific crude rates, where the weights are the proportions of persons in the 
corresponding age groups of a standard million population. To compare results from different 
populations or studies, cancer rates are generally standardized against ages distributed either into 
5-year age groupings or single years of age (NCHS) (United Stated Bureau of the Census, 1996). 
The rates adjusted by the U.S. 2000 population are higher than the rates adjusted by the 1970 
standard population because the proportion of older people, among whom cancer is more 
common, has been increasing over time in the U.S. Cancer rates adjusted for U.S. 2000 
population can provide useful and comparable results on the subject of cancer statistics in the 
U.S. 
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1.1.2 Cancer Statistics Modeling 
There is no perfect method or universally accepted model to describe temporal changes in cancer 
rates.  Limitations exist for every method or model and interpretations under alternative models 
can be inconsistent. Two major approaches to the evaluation of cancer trends are widely used:  
an age-period cohort model that examines the effects singly and together of age, period and 
cohort, and a joinpoint model that expresses age-adjusted rates as a piecewise function of time 
with or without adjustments for reporting delay.  
A major question for cancer epidemiology research is whether age-period-cohort (APC) 
analyses or joinpoint trend modeling with or without adjustments for reporting delay provides a 
better way to display cancer trends over time. Decisions about which method to use in evaluating 
cancer trends can vary depending on the goals of the evaluation.  As this thesis will demonstrate, 
there are strengths and weaknesses of each approach.  If the interest is chiefly in predicting short-
term future demand for health care, then a simple joinpoint evaluation seems sensible.  If the 
goal is to evaluate past and future causes of cancer, then more sophisticated APC modeling can 
be appropriate.  Further methodological development is required to clarify the values and 
limitations of each method.  While further research is needed to advance methods for evaluating 
cancer patterns and trends, analysis of cancer data such as that carried out here provides an 
important contribution to that effort. 
1.1.2.1 Age-Period-Cohort Model 
Fitting cancer data by a statistical model can yield useful summaries in terms of parameters in 
the model. An age-period-cohort (APC) model assumes that the logarithm of the expected rate is 
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a sum of three components representing the effects of age group, time period, and birth cohort. 
Various combinations of these three factors may be considered, and sometimes one combination 
might provide a particularly clear summary of the data (Holford, 1983). Because cancer is well 
known to increase with advancing age, age has been associated with changes in cancer rates; 
consequently, assessment of changes in cancer rates with advancing age over time has become 
the center of attention. A time period effect represents the factor that affects persons of all ages at 
essentially the same time. A cohort effect occurs when people born in the same year are exposed 
to a causative agent that renders them comparatively different from those born at another time 
(Arbeev, Ukraintseva, Arbeeva, & Yashin, 2005). The APC model has been frequently used to 
characterize cancer incidence in terms of temporal patterns associated with age, calendar year, 
and birth cohort. 
1.1.2.2 Joinpoint Regression Model 
Joinpoint regression is used to summarize long-term cancer trends and determine whether there 
are characteristic breaks in the slope over different time periods. This approach fits a linear 
regression function on a log scale with unknown join points, assuming constant variance and 
uncorrelated errors (Kim, Fay, Feuer, & Midthune, 2000). The program starts with the minimum 
number of joinpoint (e.g. 0 joinpoints, which is a straight line) and tests whether more joinpoints 
are statistically significant and must be added to the model (up to a maximum number of 
joinpoints specified by a user) (National Cancer Institute, 2005b). Using joinpoint models, one 
can determine the number of significant joinpoints and estimate rates of change of cancer 
incidence or mortality during segments of time between adjacent joinpoints. 
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1.1.2.3 Reporting-delay Adjusted Model 
Reporting delay refers to the time elapsed before a diagnosed cancer case is reported to the 
cancer registry. According to NCI, the standard time delay between cancer diagnosis and the first 
report of cancer incidence data to the public is about 2 years. The information on cases from 
prior diagnosis years is updated in subsequent releases of the SEER data (Clegg, Feuer, 
Midthune, Fay, & Hankey, 2002). However, reporting delay and reporting error hamper the 
accuracy and timing of reporting cancer cases. Delayed reports have been a concern for persons 
diagnosed in recent years since cancer rates from these years correspond to the largest group of 
underreported cancer cases. Cancer incidence adjusted for reporting delay can correct current 
cancer counts and anticipate future corrections. For each one of cancer sites, several possible 
covariates (including age, race, and gender) have been considered by NCI investigators in 
prediction models of delay probabilities. Generally, reporting delay has been greatest for non-
whites, and for screening detected cancers, such as prostate and breast (Clegg, Feuer, Midthune, 
Fay, & Hankey, 2002).  NCI investigators evaluated reporting delay within the SEER system by 
fitting covariates to annual data between 1983 and 2005 and retrospectively correcting these with 
the counts recorded two years later. The model that minimized the sum of squared prediction 
errors is chosen as the final model (National Cancer Institute, 2007a).  
1.1.3 Geographic Information System 
Geographic Information System (GIS) is a system used for input, storage, query, manipulation, 
and output of geographic information. It is a practical illustration of combining software, data, 
and user to solve a problem, support a decision, and help to develop a plan. GIS is being used 
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with increasing frequency in public health, especially environmental health research. GIS can be 
applied to epidemiologic studies to define study population and geographic units, to estimate 
environmental levels of target contaminants, and to identify source and potential routes of 
exposure that relate to health consequences (Nuckols, Ward, & Jarup, 2004).  
1.1.3.1 Mapping and Visualization 
Mapping is the most widely used GIS technique in public health studies. GIS mapping 
techniques attempt to describe diseases or estimated outcomes on geographical maps which can 
identify different values by geographic units. Cloropeth (graduated colored) maps, proportional 
circles, quartile or percentile maps are generally used to describe the distributions of data. 
Continuous cartogram provides a distorted or weighted map with geographic regions sized 
according to a statistical parameter, for instance size of the population, but in a way that keeps 
the map recognizable. 
1.1.3.2 Rate Smoothing 
Smoothing techniques aim to remove the effects of the varying population sizes across the areas 
and to maintain stability of estimated rates in small areas. There are two methods of smoothing. 
One is Empirical Bayes smoothing. Another method uses a spatial filter (ratio smoothers) to 
estimate the rate at a given point by including observations at neighboring points within a fixed 
distance. 
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1.1.3.3 Spatial Autocorrelation Analysis 
Spatial autocorrelation analysis includes tests and visualization of both global (test for clustering) 
and local (test for clusters) Moran’s I statistic. The Moran’s I statistic is used to find significant 
patterning but without designating any particular location as clustered.  As the formal test for 
spatial dependence, Moran’s I determines if the data are randomly distributed throughout a given 
region, or if there some nonrandom clustering is evident.  Significance within Moran’s I estimate 
indicates that there is a spatial dependence within the data.  A test for cluster is designed to 
identify the locations of the clusters (or the spatial outliers) (Anselin, 2004). The global test is 
visualized by means of a Moran scatter plot, in which the slope of the regression line 
corresponds to Moran’s I. The significance test is based on a permutation test (Anselin, Syabri, 
& Kho, 2006).  
The local indicator of spatial autocorrelation (LISA) is used to identify local spatial 
clusters and outliers with respect to the measure of global association. It also includes several 
options for sensitivity analysis. For each location, the LISA value allows for the computation of 
its similarity with its neighbors and also to test its significance. The output of LISA analysis 
includes a Moran scatter plot and box plot depicting the distribution of the local statistics. Local 
Moran I estimates can also be displayed on a map to identify clusters (Anselin, 1995).  
1.1.3.4 Spatial Data Modeling 
Methods of identifying geographic relationships include spatial correlation analysis and spatial 
regression models. A commonly used method is Pearson’s correlation coefficient. The Pearson’s 
correlation coefficient between two spatial variables (which are both normally distributed) and 
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the correct significance can be calculated to identify two factors that vary in a similar manner 
with respect to geographic location. Spearman’s rank coefficient correlation is used when the 
data are not normally distributed. Spatial regression analysis modifies linear regression, multiple 
regression, or logistical regression techniques in order to take account of spatial autocorrelation. 
Techniques are available to take account of the spatial structure of either the dependent or 
independent variables specified by a model.  
1.2 CANCER LITERATURE REVIEW 
It was recently reported that the cancer mortality continues to decline in the U.S. while the rate 
of newly diagnosed cancer is holding steady. In the Annual Report to the Nation on the Status of 
Cancer, 1975-2002, the death rate for all cancers combined dropped 1.1 percent annually from 
1993 to 2002 (National Cancer Institute, 2005a). According to the report, declines in death rates 
reflect progress in prevention, early detection, and treatment; however, not all racial and ethnic 
segments of the U.S. population benefited equally. Delay-adjusted incidence for all cancers 
combined was on the rise until 1992, and began to decline between 1992 and 1995 and then 
stabilized in 1995 (H. L. Howe et al., 2006). It was stable in men from 1995 to 2003 and it 
increased 0.3 percent annually in women from 1987 to 2003. Changes in cancer incidence may 
result from changes in the prevalence of health behaviors and from changes in detection practices 
due to the introduction or increased use of screening and/or diagnostic techniques. Based on 
ACS estimates in 2007, cancers of the prostate and breast are the most frequently diagnosed 
cancers in men and women, respectively, followed by lung and colorectal cancer (American 
Cancer Society, 2007b). These four combined cancers are related to screening technologies and 
 11 
tobacco smoking. Therefore, analyzing time trends of these cancer sites can provide us with tools 
to assess whether primary prevention, early detection, and treatment have helped to reduce 
cancer incidence and mortality. 
1.2.1 Cancer Related to Tobacco Smoking 
Based on the article "Cigarette Smoking Among Adults-United States, 2004", the rates of 
smoking among men (56.9%) were much higher than among women (28.4%) in 1955, but the 
gender difference began to diminish as the rates among men declined and the rates among 
women rose or declined slower (Centers for Disease Control and Prevention, 2005a). In 2005, 
regardless of race or ethnicity, prevalence of current cigarette smoker was 23.9% among men 
and 18.9% among women. Specifically, current smoking is higher in non-Hispanic black men 
(26.7%) than non-Hispanic white men (24.0%) and is higher in non-Hispanic white women 
(20.0%) than in non-Hispanic black women (17.3%) (Centers for Disease Control and Prevention, 
2006c). The report also indicated that prevalence of cigarette smoking among U.S. adults did not 
change from 2004 to 2005. The adult prevalence might represent a stall in the decline in current 
cigarette smoking during the preceding 8 years and mirrors a lack of decline in smoking among 
adolescents since 2002 (Centers for Disease Control and Prevention, 2006a) . 
Cancer of the oral cavity and pharynx, esophagus, pancreas, larynx, lung and bronchus, 
urinary bladder, and kidney and renal pelvis have been associated with tobacco smoking (Centers 
for Disease Control and Prevention, 2006b; Dinse, Umbach, Sasco, Hoel, & Davis, 1999).Data 
from the SEER program show that cancer incidence for lung, larynx, oral cavity, pharynx, and 
bladder has decreased dramatically in white men from 1991 through 1995. Incidence for these 
cancer sites also declined in white women with the exception of lung cancer. Black men and 
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women generally experienced similar decreased patterns, but oral cavity cancer continued to 
increase in men, as did larynx cancer in women (McKean-Cowdin, Feigelson, Ross, Pike, & 
Henderson, 2000). According to the estimates by ACS in 2007, among the top ten sites with 
respect to cancer mortality, are cancer of lung and bronchus, pancreas, esophagus, urinary 
bladder, and kidney, which together account for 47% of cancer deaths in men. Cancer of lung 
and bronchus and pancreas accounts for 32% of cancer deaths in women (American Cancer 
Society, 2007b). Many cancer deaths could be reduced further because smoking is a leading 
factor among preventable cancer causes.  
1.2.2 Cancer Related to Screening Techniques  
Prostate, breast, cervix uteri, and colon, and rectal are four recommended sites for early cancer 
detection in asymptomatic people (American Cancer Society, 2007a). Among men, screen-
detectable cancers, prostate cancer and colorectal cancer, account for 18% of cancer deaths; in 
women, colorectal cancer and breast cancer account for 25% of all cancer deaths. Meanwhile, 
these cancer sites account for 39% of cancer cases in men and 37% in women (American Cancer 
Society, 2007b). It has been documented that among men, incidence for prostate cancer 
increased during the 1990s, while that of colorectal cancer decreased (Edwards et al., 2005). 
Among women for all races combined, incidence for cancer of the cervix uteri and colon-rectum 
has decreased between 1992 and 2002.  
Regarding female breast cancer, the incidence rate increased by 0.4% annually from 1987 
through 2002, which is less than the 3.7% annual increase from 1980 to 1987 (Edwards et al., 
2005). Within the updated SEER data, breast cancer incidence for all races combined has 
decreased 2.7% annually between 2000 and 2004 (National Cancer Institute, 2006c). However, 
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in recent five years, breast cancer incidence declined among white women (3.1% per year) but 
increased among black women (1.2% per year). Elucidating racial disparity of female breast 
cancer trend needs further work. The last 5 years data of the Women’s Health Initiative (WHI) 
clinical trial demonstrated that there were excess risks of breast cancer and cardiovascular 
disease among Hormone Replacement Therapy (HRT) users. Study has shown that HRT use has 
decreased significantly immediately post-WHI study since 2002 (Kim, Fay, Feuer, & Midthune, 
2000) .Whether declined breast cancer incidence in recent years associate with decreased HRT 
prescription, and whether the decline differs by race requires evaluation by the epidemiology 
data existing today and in the future.  
In general, mortality for cancer of the prostate among men, breast and cervix uteri among 
women, and colon and rectum in both men and women have decreased in recent years. Studying 
changes in cancer related to screening technologies will help us to evaluate the effectiveness of 
cancer screening program and provide insight into cancer prevention and control. 
1.2.3 Cancer Unrelated to Smoking or Screening 
Studying a grouping of cancers unrelated to smoking and screening is important because any 
observed effects are presumably uncorrupted by changes of smoking behavior or screening 
practice. Not all of the cancers we have treated as smoking-related are in fact completely caused 
by smoking. After excluding cancers linked to tobacco smoking (oral cavity and pharynx, 
esophagus, larynx, lung and bronchus, pancreas, bladder, and kidney and renal pelvis) and 
screening technologies (breast, prostate, cervix uteri, and colon-rectum), incidence for the 
remaining cancer sites (mainly are non-Hodgkin’s lymphoma, melanoma of the skin, leukemia, 
thyroid  and corpus and uterus) changed little in white women, but it has risen 0.5% per year in 
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black women, and 1.7% per year in white men and 2.1% per year in black men between 1975 
through 1994 (Dinse, Umbach, Sasco, Hoel, & Davis, 1999). Different cancer patterns between 
men and women have been observed, with men showing larger increases in cancer incidence 
than women, Gender-specific risk factors, particularly those related to occupation or the 
environment, require further exploration.  
1.2.4 Non-Hodgkin’s Lymphoma 
As cancer occurrence and death rates continue to decrease for all cancer sites combined and for 
most individual cancers in recent decades in the United States, NHL has been documented a 
substantial increase of incidence and mortality (National Cancer Institute, 2007b). NHL is now 
the fifth most common malignant neoplasm among males and females (American Cancer Society, 
2007b). High rates of lymphoma have been observed among individuals with autoimmune 
disease, organ transplant, and primary or acquired immunodeficiencies (Fisher & Fisher, 2004). 
Infectious agents are being regarded as established causes of NHL (Engels, 2007). Epstein-Barr 
virus (EBV) is an important agent in the etiology of NHL. EBV infection is associated with 
increasing risk of NHL, especially Burkitt’s lymphomas, central nervous system (CNS) 
lymphomas, T-cell NHL and NHL in individuals with immune dysfunction. Infections with 
Human T-cell leukemia/lymphoma virus type 1 (HTLV-1), Hepatitis C virus (HCV), Human 
herpes virus 8 (HHV8), and Helicobacter pylori have also been related to NHL risk (Baris & 
Zahm, 2000; Grulich & Vajdic, 2005). However, the relationship has been restricted to specific 
NHL subtypes and only account for a limited proportion of the NHL increases. 
The role of environmental exposure may in part explain NHL incidence trends. Exposure 
to pesticides, herbicides, insecticides, and fungicides are also related to increased risk of NHL 
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(De Roos et al., 2003; Fritschi et al., 2005; Hardell & Eriksson, 1999; Rafnsson, 2006; Schroeder 
et al., 2001). Epidemiologic studies have shown that polychlorinated biphenyl (PCB) levels in 
peripheral blood or adipose tissue are associated with increased risk of NHL (De Roos et al., 
2005; Quintana et al., 2004; Rothman et al., 1997) Use of hair dyes among women has been 
suggested as a risk factor for NHL, especially follicular type, B-cell and low-grade lymphomas. 
This is consistent with an extensive animal literature testing various components of hair dye 
toxicologically (Zhang et al., 2004). However, the evidence of a limited increase in the risk of 
NHL among personal hair dye users is inconsistent (Takkouche, Etminan, & Montes-Martinez, 
2005). Elucidation of clear etiologic factors and their mechanistic role in NHL pathogenesis has 
been challenging and needs further investigations. 
1.2.5 Arsenic and Cancer Risk 
Arsenic is a metalloid found in water, soil, and air from natural sources and anthropogenic 
activities such as mining and agriculture applications. Populations exposed to arsenic from 
geologic contamination of water are found around the world, including locations in Taiwan, 
India, Inner Mongolia, Chile, Mexico, Argentina, and California and other parts of the western 
U.S. (Cantor, 1997). Arsenic can cause acute and chronic adverse health effects including 
multiple cancers (World Health Organization, 2001). Arsenic carcinogenesis has been developed 
by the animal model. Possible modes of action of arsenic carcinogenesis may include 
chromosomal abnormalities, oxidative stress, altered DNA repair, altered DNA methylation 
patterns, altered growth factors, enhanced cell proliferation, promotion/progression, gene 
amplification, and suppression of p53 (Kitchin, 2001). Other potential mechanisms also include 
genetoxicity, co-carcinogenesis, and tumor promotion (Hughes, 2002). Although the exact 
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mechanisms of arsenic action are not well known, arsenic contaminated drinking water is one of 
the major concerns in public health.  
1.2.5.1 Arsenic Exposure Measurement 
Among methods to test arsenic levels in human body, urinary arsenic can be a conclusive 
biomarker of recent exposure. In addition, recent systemic absorption can be measured by 
amounts of arsenic in hair and toenail or fingernail clippings (Robson, 2003). Quantification of 
inorganic arsenic and its metabolites in urine can provide important information on 
detoxification mechanisms that influence the actual doses to tissue and potential risk for chronic 
health effects (Chappell et al., 1997). It has also shown that toenails can provide an integrated 
measure of internal inorganic arsenic exposure and reflect all sources of exposure, including 
drinking water, diet, and occupation (Garland et al., 1993; Michaud et al., 2004). However, data 
for long-term arsenic exposure need to combine exposure duration, dose, exposure route and 
history, arsenic source assessment, and individual health history. Accurate measurement of 
arsenic in drinking-water at levels relevant to health also requires sophisticated laboratory 
analytic techniques. Analytical quality control and external validation are critical. However, 
reliability of field methods is yet to be fully evaluated (World Health Organization, 2001). 
Accurate measurement of arsenic exposures remains challenging. 
1.2.5.2 Epidemiology Study 
The latency period in humans of arsenic-related carcinogenesis is considered to be 30-50 years 
(Tapio & Grosche, 2006). Due to the long latency, studies on dose-response relationship between 
arsenic and internal or external cancers were based on areas with a long exposure history such as 
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Taiwan and Chile (Chiou et al., 1995; Ferreccio et al., 2000; Wu, Kuo, Hwang, & Chen, 1989). 
The relationship between arsenic exposure in drinking water and cancer risk has been 
documented from these studies. However, US-based epidemiologic studies have not been able to 
provide convincing evidence that ingested arsenic through contaminated water is associated with 
cancer risk (Bates, Smith, & Cantor, 1995; Lamm et al., 2004; Lewis, Southwick, Ouellet-
Hellstrom, Rench, & Calderon, 1999). More recently, elevated cancer rates from high levels of 
arsenic in drinking-water in Bangladesh is attracting much attention to the issue of arsenic-
related cancer risk. The number of people consuming arsenic-rich water in Bangladesh has 
increased dramatically since the 1970s due to well-drilling and population growth (Rahman et al., 
2001). The most commonly manifested disease so far is skin lesions. Increased risk of skin and 
internal cancers has not been observed, but they are likely to become a principal human health 
concern arising from arsenic exposure. 
In 2001, after considering the analyses and risk assessment on arsenic from the National 
Research Council, the U.S. Environmental Protection Agency lowered the maximum 
contaminant level (MCL) for arsenic in drinking water from 50 μg/l to 10 μg/l (United Stated 
Environmental Protection Agency, 2001). Health risks associated with inorganic arsenic 
exposures; particularly at relatively low exposure levels in the U.S. population has generated 
discussion and debate. More studies are needed to estimate the contributions of arsenic exposure 
to cancer risk. 
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1.3 SPECIFIC AIM 
This research uses statistical models and Geographic Information System techniques to analyze 
population-based cancer incidence and mortality data. The research encompasses three discrete, 
but related projects (below):  
1.3.1 Project#1  
Smoking-associated cancer includes primary site-specific cancer where incidence is typically 
higher among persons with a personal smoking history. Screening-detected cancer includes 
primary site-specific cancer where shifts in cancer incidence can be attributed, at least in part, to 
variation in the use of medical technologies for detecting early or sub-clinical cancer. The third 
cancer category includes all primary site-specific cancer not belonging to either the smoking-or 
screening-related cancer categories which constitutes a collection where variation in incidence 
cannot easily be attributed to changes in tobacco use or to changes in medical care. Therefore, 
any variation observed in the occurrence of cancer in the other cancer category can be conceived 
as a possible consequence of general environmental influences on cancer risk, such as NHL. 
Descriptive analyses of U.S. cancer rates using Joinpoint models have been annually 
conducted and reported by NCI researchers. However, by applying APC models, an alternative 
statistical approach, and by categorizing multiple site-specific cancers into three mutually 
exclusive cancer groups, Project #1 aims to distinguish itself from previous reports by providing 
a potential means for isolating cancer risk effects due to general environmental exposures. 
Project#1 specific aims are: 
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a) Perform APC analysis to summarize U.S. cancer trends for three broad categories that 
include smoking-related cancer, screening-related cancer, and cancer unrelated to 
smoking and screening 
b) Analyze recent U.S. NHL cancer rates by characterizing race- and gender-specific 
incidence and mortality in terms of temporal patterns associated with age, calendar year 
(period), and year of birth (cohort). 
1.3.2 Project#2 
Previous analyses of SEER data and studies in other countries have documented time-related 
increases in NHL incidence in the United States. Using NHL incidence data from Pennsylvania, 
which is not included in SEER registry, one can identify whether the trends observed elsewhere 
also hold true in a statewide cancer registry. Associating the characteristics with county-specific 
NHL incidence, ecologic study is used to identify possible NHL risk factors in Pennsylvania. 
Project #2 specific aims are: 
a) Apply APC and Joinpoint regression models to characterize race- and gender-specific 
NHL incidence in terms of temporal patterns in Pennsylvania and SEER registry during 
the 1985-2004 time periods. 
b) Compare demographic patterns and temporal trends of NHL incidence between 
Pennsylvania and SEER registry during the 1985-2004 time periods according to the 
results from APC and Joinpoint models. 
c) Use multiple linear regression models to evaluate factors associated with NHL incidence 
in Pennsylvania during the 1985-2004 time periods. 
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1.3.3 Project #3 
Ground water contamination is the main route of arsenic exposure. Ground water in Idaho 
contains elevated levels of naturally occurring arsenic by geographic conditions and also by 
human agriculture activities. In Idaho, 95% of drinking water comes from ground water sources 
and arsenic exposure through ground water has been a concern. Geographic Information System 
(GIS) techniques are being used to visualize the geographic distribution of an exposure or 
disease. Spatial analytic method applied to the field of public health, though relatively rare, can 
help to develop information on interpreting exposure and health consequences. The methods we 
identify here are used to summarize gender- and county-specific cancer incidence and whether it 
is related to the arsenic level in ground water in Idaho. Project #3 specific aims are:   
a) Apply GIS and spatial analytic technologies to describe geographic and temporal patterns 
in Idaho cancer incidence during the 1990-2005 time periods. 
b) Use GIS techniques to visualize geographic distributions of arsenic levels in ground 
water in Idaho during the 1990-2005 time periods.  
c) Use spatial analytic methods to evaluate risk factors associated with cancer incidence in 
Idaho during the 1990-2005 time periods. 
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2.1 ABSTRACT 
Introduction: Studies of cancer incidence and mortality trends can be used to characterize 
current and future demands for health care and to suggest etiologic hypotheses about avoidable 
causes of any unexplained patterns. Methods: Using United States (U.S.) 1979-2003 cancer 
incidence and 1969-2003 cancer mortality data, we fit gender- and race-specific age-period-
cohort models to summarize age-specific rates for three broad cancer categories, tobacco-related 
cancer, screen-detectable cancer, and cancer in neither the tobacco-related or screen-detectable 
categories. Results: Tobacco-related cancer incidence declined among men and increased among 
women. Screen-detectable cancer incidence increased, more rapidly among men than women. 
For cancer unrelated to tobacco or screening, incidence increased in every gender-race group, 
with average annual percentage changes (AAPC) of 0.99 and 0.72 percent per year in white and 
black men and 0.92 and 0.79 percent per year in white and black women. Generational risks of 
these cancers are between 1.2 and 1.3 fold higher when one generation compared to previous 
generation.  AAPC estimates for incident non-Hodgkin’s lymphoma (NHL), a cancer unrelated 
to tobacco or screening, were 2.33 and 3.17 percent per year in white and black men and 1.92 
and 3.29 percent per year in white and black women. Except for NHL and female tobacco-
related cancer, mortality decreased over time. Conclusions: Underlying rates of cancer not 
related to smoking or screening are projected to increase. Persons over age 65 are among the 
fastest growing segment of the population today, a segment in which four out of every five cases 
of cancer will occur.  The demand for cancer treatment will increase as a result of this 
demographic shift alone.  Hypotheses should be generated and tested regarding underlying, 
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avoidable or modifiable risk factors, including environmental factors, that may account for some 
of these unexplained patterns of cancer unrelated to tobacco or screening. 
2.2 INTRODUCTION 
Analyses of cancer trends have been used to evaluate progress against cancer (H. L. Howe et al., 
2006). A recent analysis showed cancer incidence increasing between 1975 and 1992, cancer 
incidence stable between 1992 and 2003, and cancer mortality declining since the early 1990s (H. 
L. Howe et al., 2006). Analyses of cancer trends involving specific organ sites or population 
subgroups have been used to study etiology and to measure health disparities (Edwards et al., 
2005). However, the interpretation of population-based cancer statistics is complicated by 
variable case reporting, changes in medical practice, and a multiplicity of risk factors, including 
those related to personal behaviors and those related to carcinogens in air, water, and food. 
One simplifying approach divides primary site-specific cancer into three broad 
categories, tobacco-related cancer, screen-detectable cancer, and cancer unrelated to tobacco or 
screening. Tobacco-related cancer includes 100% of all primary cancers having causal 
association with current and former tobacco use. Excluding tobacco-related cancer, screen-
detectable cancer includes primary cancers where shifts in incidence can be attributed, at least in 
part, to variation in the use of medical technologies for early cancer detection. By definition, 
cancer unrelated to tobacco or screening is a residual category constituting a disease collection 
where variation in incidence can not easily be attributed to changes in tobacco use or in medical 
care. Compared to all-sites of cancer combined, occurrence of cancer unrelated to tobacco or 
screening may be a more specific indicator of general environmental influences on cancer risk. 
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An similar analysis but less extensive was performed by Dinse et al. (Dinse, Umbach, 
Sasco, Hoel, & Davis, 1999), using Poisson regression techniques to model U.S. 1975 through 
1994 age-specific incidence in terms of age group, calendar time period, and birth cohort. They 
calculated temporal average annual percentage changes (AAPC) in incidence for cancer 
unrelated to tobacco or screening (Dinse, Umbach, Sasco, Hoel, & Davis, 1999). Estimates of 
AAPC were higher among white and black men (1.7 and 2.1 percent per year), than white and 
black women (0.1 and 0.5 percent per year). Gender-dependent occupational, environmental, or 
behavioral risk factors may account for this differential trend in cancer unrelated to tobacco or 
screening. 
U.S. incidence rates for non-Hodgkin’s lymphoma (NHL), an important example of 
cancer unrelated to tobacco or screening, are increasing dramatically (H. L. Howe et al., 2006; 
Muller, Ihorst, Mertelsmann, & Engelhardt, 2005), 2.4 percent and 4.2 percent per year among 
white and black women and 4.7 percent and 6.4 percent per year among white and black men, 
according to the analysis of Dinse et al. (Dinse, Umbach, Sasco, Hoel, & Davis, 1999). Possible 
explanations for this trend include improved diagnosis, changes in disease classification, use of 
immune-compromising medical therapies, and human immunodeficiency virus (HIV) infection 
(Fisher & Fisher, 2004; Grulich & Vajdic, 2005; Hennessy, Hanrahan, & Daly, 2004). However, 
in the opinion of some analysts, these factors only partially explain recent NHL trends (Clarke & 
Glaser, 2002; Muller, Ihorst, Mertelsmann, & Engelhardt, 2005). 
Using methods described by Dinse et al. (Dinse, Umbach, Sasco, Hoel, & Davis, 1999) , 
this study summarizes U.S. temporal trends for tobacco-related cancer, screen-detectable cancer, 
and cancer unrelated to tobacco or screening. This study extends the work of Dinse et al. by 
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including up-to-date incidence data (1979-2003), corrected for reporting delay, and by 
examining mortality, as well as incidence. 
2.3 MATERIALS AND METHODS 
2.3.1 Cancer Data 
SEER*Stat (version 6.2.4) (Surveillance Epidemiology and End Results (SEER) Program, 
2006b, 2006c) and SEER*Stat databases were used to obtain race-, sex-, age-, year-, and cancer 
site-specific cancer incidence and mortality counts. SEER also provided race-, sex-, age-, year-, 
and county-specific population estimates (National Cancer Institute, 2006a) and race-, sex-, age-, 
year-, and cancer site-specific correction factors for reporting delay (Surveillance Epidemiology 
and End Results (SEER) Program, 2006a). 
The current SEER Program collects and reports on cancer incidence and survival data 
from 15 population-based central cancer registries that cover 26 percent of the U.S. population 
and includes 23 percent of African Americans, 40 percent of Hispanics, 42 percent of American 
Indians and Alaska Natives, 53 percent of Asians, and 70 percent of Native Hawaiian and other 
Pacific Islanders (United States Department of Health and Human Services (DHHS), 2006). 
Analyses of cancer incidence were restricted here to the original nine SEER populations, which 
included five states (Connecticut, Iowa, New Mexico, Utah, and Hawaii), three metropolitan 
areas (Detroit, San Francisco-Oakland, and Atlanta), and a 13-county Seattle-Puget Sound 
region. Selections according to cancer primary site used the “SEER Incidence Site Recode ICD-
O-3 (1/27/2003)” (http://seer.cancer.gov/siterecode), a coding scheme that maps ICD-O-3 
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primary site and histology data (converted from ICD-O-2, where necessary) into conventional 
primary site groupings, groupings which are consistent over time. Similar to Dinse et al. (Dinse, 
Umbach, Sasco, Hoel, & Davis, 1999), the tobacco-related cancer category included 100 % of all 
of the following sites: invasive cancers of the oral cavity and pharynx (ICD-O-3 primary site 
C000-148), esophagus (C150-159), pancreas (C250-259), larynx (C320-329), lung and bronchus 
(C340-349), urinary bladder (C670-679), and kidney and renal pelvis (C649, C659). The screen-
detectable category included invasive cancers of the prostate (C619), female breast (C500-
C509), cervix (C530-C539), and colon-rectum (C180-189, C199, C209, C260). Both categories 
excluded lymphoma (ICD-O-3 histology code 9590-9989). Cancer unrelated to tobacco or 
screening included all instances of invasive cancer not in the tobacco-related or screen-detectable 
cancer categories. NHL, a subgroup within the category of cancer unrelated to tobacco or 
screening, included cancers of ICD-O-3 histology 9590-9596 and 9670-9729, regardless of 
primary site, and cancers of ICD-O-3 histology 9823 (B-cell chronic leukemia) and 9827 (adult 
T-cell leukemia/lymphoma) at any ICD-O-3 primary site except C024, C098-C099, C111, C142, 
C379, C420-C422, C424, or C770-C779. 
Analyses of cancer mortality covered the entire U.S., including nearly all 50 states and 
the District of Columbia. Selections according to cause of death used the “SEER Cause of Death 
(COD) Recode 1969+ (9/17/2004)” (http://seer.cancer.gov/codrecode), a scheme that maps ICD-
9 (converted from ICD-8, where necessary) and ICD-10 cause of death codes into conventional 
cause of death categories, categories which are consistent over time. 
Cancer incidence and mortality analyses were restricted to black and white races. 
Analyses of cancer incidence and mortality included only cancers diagnosed or deaths occurring, 
respectively, between ages 20 and 84 years. We did not attempt to model cancer endpoints 
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occurring after age 84 years, a setting where the recognition and classification of cancer are 
particularly vulnerable to variability in medical care. Also, we did not attempt to model cancer 
endpoints before age 20 years, because of the relative infrequency of cancer in these youngest 
age groups. To avoid age-period tabulations with empty cells, it also became necessary to 
exclude 20-24 year-old black men from the analysis of screen-detectable cancer incidence. 
For every possible combination of cancer category (tobacco-related cancer, screen-
detectable cancer, cancer unrelated to tobacco or screening, and NHL), sex (men and women), 
race (black and white), and 5-year age grouping between 20-24 and 80-84 years, we calculated 
age-specific cancer incidence for each of five 5-year time periods between 1979-1983 and 1999-
2003 and age-specific cancer mortality for each of seven 5-year time periods between 1969-1973 
and 1999-2003. To account for reporting delay, we multiplied each directly calculated cancer 
incidence rate by the appropriate correction factor (see above and reference (Clegg, Feuer, 
Midthune, Fay, & Hankey, 2002). 
2.3.2 Age-Period-Cohort Analysis 
We fit separate age-period-cohort (APC) models to age-specific cancer incidence and to age-
specific cancer mortality rates, for every possible combination of cancer category, sex, and race 
(see Statistical Appendix). The APC models estimated the natural logarithm of age-specific 
cancer incidence or mortality rate as a function of thirteen 5-year age groups (between 20-24 and 
80-84 years), five-year time periods (five time periods for incidence, seven for mortality), and 
overlapping 10-year birth cohorts (17 birth cohorts for incidence, 19 for mortality). Expressing 
the natural logarithm of the population at risk as an offset variable, we used Poisson regression (a 
generalized linear model with a log link function and Poisson response probability distribution, 
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implemented in PROC GENMOD, SAS Version 9.1, Cary, N.C.) to fit cancer incidence or 
mortality counts to variables representing age group, time period, and birth cohort. Using the 
method described by Dinse et al. (Dinse, Umbach, Sasco, Hoel, & Davis, 1999), we 
parameterized the APC model in terms of separate linear effects due to age group, time period, 
and birth cohort (each expressed as an integer ordinal variable) and age group-specific, time 
period-specific, and birth cohort-specific deviations added to the linear effects due to age group, 
time period, and birth cohort, respectively (see Statistical Appendix). Using the iterative 
approach described by Breslow (Breslow, 1984), we fit the extra-Poisson model if, according to 
the Pearson chi-square goodness of fit test (p<0.05), the simple Poisson model produced over-
dispersed residuals. To test the statistical significance of the collective contribution made by a 
particular parameter set (age group, time period, or birth cohort), we dropped the relevant 
parameter set from the full age-period-cohort model and constructed the appropriate F-test from 
the change produced in the Pearson chi-square goodness of fit test statistic. 
The APC model is overdetermined, limiting direct interpretation of the individual 
parameters estimated by the model. There is no way to determine whether any single one of the 
parameters—age, period, or birth cohort-- could on its own be a sufficient determinant of the 
outcome.   We view age, period, and cohort effects as being smooth, continuous functions of  
time. Although these smooth functions could have very complex  shapes, each set of effects still 
can be described by a straight line and a collection of deviations about that line. It turns out that  
the individual slopes of the 3 straight lines are not identifiable,  but the deviations about those 
lines are identifiable. Furthermore, even though we can not uniquely estimate the individual 
slopes associated with the age, period, and cohort effects, we can uniquely estimate certain 
combinations of them, such as the sum of the age and period slopes and the sum of the period 
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and cohort slopes. Thus, we can uniquely estimate the drift (Ddrift) (i.e. the sum of the period and 
cohort slopes) and use this to summarize long-term time trends. Drift generally involves 
contributions from time period and birth cohort effects, but we can not estimate the proportions 
attributable to each. In addition, we can use the patterns of deviation to attribute certain 
information to age, period and cohort effect individually. 
Thus, our parameterization of the APC model (see Appendix A: Statistical Appendix) 
uniquely identified the sum Ddrift of the two parameters representing the linear effects due to time 
period and birth cohort. Having modeled age-specific rates for 5-year age groups over 
contiguous 5-year time periods, we used the transformation ( )1100 5/ −driftDe  to estimate the 
average annual percentage change (AAPC). The AAPC represents the age-independent relative 
change in cancer risk associated with a temporal change of 1 year in duration. The Wald 95 
percent confidence interval for the AAPC was estimated at ( ) ⎟⎠⎞⎜⎝⎛ −
± 1100 5/96.1 driftD
driftDe σ , where driftDσ  
is the estimate of the standard error of Ddrift.  
As a function of calendar year, we plotted, for each APC model, the time period-specific 
deviations added to the linear effects due to time period. As a function of year of birth, we also 
plotted the birth cohort-specific deviations added to the linear effects due to birth cohort. As 
noted above, the linear effect due to time period can be incorporated into the linear effect due to 
birth cohort. Therefore, the F-test applied to the time period parameter set can be interpreted as a 
statistical test of the curvature observed in the time period-specific deviation plot (H0: perper 1N −D =0, 
see Statistical Appendix). Similarly, the F-test applied to the birth cohort parameter set can be 
interpreted as a statistical test of the curvature observed in the birth cohort-specific deviation plot 
(H0: cohcoh 1N −D =0, see Statistical Appendix). Regions of progressive increase and decrease were 
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interpreted as sequential time periods or birth cohorts exerting positive and negative pressure, 
respectively, on cancer risk (see Statistical Appendix). A plot with deviations decreasing over 
recent time periods or later birth cohorts was interpreted as an indicator of a time-related factor 
that possibly predicts diminishing risk for future time periods or birth cohorts. 
2.4 RESULTS 
2.4.1 Effect of Reporting Delay 
As expected, estimates of average annual percentage change (AAPC) were increased by 
adjusting incidence for reporting delay (Appendix Table B-1). When examined according gender 
and race, increases in AAPC were small (≤0.07 percent per year) for tobacco-related and screen-
detectable cancer, intermediate (between 0.11 and 0.13 percent per year) for cancers unrelated to 
tobacco or screening, and substantial (between 0.17 and 0.19 percent per year) for NHL. 
Adjustments for reporting delay did not affect inferences regarding the statistical significance of 
time period or birth cohort parameter sets (data not shown). All results which follow adjusted for 
reporting delay. 
2.4.2 Tobacco-related Cancer 
Age-adjusted tobacco-related cancer incidence and mortality were higher in men than women 
and higher in blacks than whites (Appendix Figure B-1). Age-adjusted incidence and mortality 
rates have been decreasing in men and increasing in women. However, beginning in 1989, the 
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rate of increase slowed in women. Tables 2-1 and 2-2 and Figures 2-1 to 2-4 contain the results 
from APC models. APC models confirmed generally decreasing tobacco-related cancer risk in 
men (AAPC estimates ranging between -0.89 and -1.47 percent per year) and increasing risk in 
women (AAPC estimates ranging between 0.18 and 0.83 percent per year). Except for incidence 
in black women and mortality in white men, both birth cohort and time period parameters 
significantly (p<0.05) improved the fit of APC models. Except for incidence in white women and 
black men, parameter deviations added to linear effects appeared either flat or downward sloping 
over recent birth cohorts and time periods. With respect to the tobacco-related cancer incidence, 
birth cohort parameter deviations sloped upward beginning with the 1949-1958 white female and 
the 1964-1973 black male birth cohorts (Figure 2-1). 
2.4.3 Screen-detectable Cancer 
Age-adjusted screen-detectable cancer mortality was highest in black men, intermediate in black 
women, and lowest in whites (Appendix Figure B-2). Recent times showed decreasing age-
adjusted mortality in each sex-race group, but, in black men, this decline followed a period of 
prominent increase. Generally increasing over time, age-adjusted incidence peaked prominently 
in men between 1989 and 1995. APC models confirmed generally increasing incidence, more so 
in men (AAPC 2.51 to 3.02 percent per year) than women (AAPC 0.10 to 0.37 percent per year; 
Table 2-1) and decreasing mortality, more so in whites (AAPC -1.10 to -1.44 in whites) than 
blacks (AAPC -0.34 to -0.83 percent per year; Table 2-2). In women, birth cohort and time 
period parameters improved APC model fit, both for incidence and mortality. In men, for blacks 
only, only birth cohort parameters improved fit. In both incidence and mortality APC models, 
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parameter deviations added to linear effects appeared either flat or downward sloping over recent 
birth cohorts and time periods (Figures 2-1 to 2-4). 
2.4.4 Cancer Unrelated to Tobacco or Screening 
Age-adjusted mortality due to cancer unrelated to tobacco or screening was higher in men than 
women and higher in blacks than whites (Appendix Figure B-3). Age-adjusted incidence was 
lowest in black women and, after 1997, intermediate in black men. Over time, age adjusted 
incidence and mortality generally trended upward and downward, respectively. APC models 
confirmed generally increasing incidence (AAPC 0.72 to 0.99 percent per year; Table 2-1) and 
decreasing mortality (AAPC -0.35 to -0.80 percent per year; Table 2-2). For mortality, birth 
cohort and time period parameters improved fit, regardless of sex and race. The fit of APC 
incidence models were not significantly worsened by ignoring birth cohort effects among white 
men or by ignoring time period effects among white or black women. For women only, positive 
slopes covering recent birth cohorts were observed in birth cohort parameter deviation plots from 
incidence models (Figure 2-1) and in time period parameter deviation plots from mortality 
models (Figure 2-4). 
2.4.5 Non-Hodgkin’s Lymphoma 
Age-adjusted NHL incidence was highest in white men, intermediate in black men and white 
women, and lowest in black women (Appendix Figure B-4). Age-adjusted incidence generally 
increased over time, although incidence flattened in men after 1990. Age-adjusted mortality 
increased with time before 1995 and, except for black women, decreased thereafter. APC models 
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confirmed generally increasing incidence (AAPC 1.92 to 3.29 percent per year; Table 2-1) and 
increasing mortality, more so in blacks (AAPC 1.39 to 1.54 percent per year) than whites (AAPC 
0.28 to 0.62 percent per year; Table 2-2). For both incidence and mortality, time period 
parameters improved fit, except for the incidence model in black women. In incidence (Figure 2-
2) and mortality (Figure 2-4) models, respectively, time period parameter deviation plots sloped 
downward after the 1989-1993 and 1994-1998 time periods. Birth cohort parameters improved 
fit only for mortality models in white men and in women, both white and black. The strongly 
positive slope connecting the 1969-1978 and 1974-1983 birth cohort parameter deviations in the 
incidence model for black women (Figure 2-1) may represent random variability in the single 
age-specific rate used to estimate the last (1974-1983) birth cohort parameter. 
2.5 DISCUSSION 
Results from APC models can be summarized, as follows, 1) tobacco-related cancer risk appears 
to decrease in men and increase in women, with recent birth cohorts of white women, and 
possibly black men, experiencing increasing pressure on incidence, 2) screen-detectable cancer 
incidence increased and mortality decreased, and 3) all other cancer incidence increased, with 
women in recent birth cohorts experiencing increasing pressure on incidence, and mortality 
decreased, but with recent time periods exerting increasing pressure on mortality in women. APC 
analysis of NHL, a subgroup of cancer unrelated to tobacco or screening, showed increasing risk, 
both incidence and mortality, with recent time periods exerting decreasing pressure on risk. 
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2.5.1 Tobacco-related Cancer 
Other analysts have noted the impact of tobacco-related cancer, particularly lung and bronchus 
cancer, on declining U.S. male cancer incidence and mortality (McKean-Cowdin, Feigelson, 
Ross, Pike, & Henderson, 2000). In a recent update, Howe et al. (H. L. Howe et al., 2006) 
observed continuously decreasing incidence and mortality in U.S. men for cancers of the lung 
and bronchus, oral cavity and pharynx, bladder and pancreas, each a tobacco-related cancer. In 
our analyses, tobacco-related cancer trends were similar in white and black men, a pattern not 
highlighted by Howe et al. (H. L. Howe et al., 2006). 
Featuring birth cohort- and time period-related effects, APC mortality analyses confirmed 
a slowing of the tobacco-related cancer epidemic in women. APC incidence analyses showed 
increasing tobacco-related cancer risk among white women born after 1949-1958, a pattern 
consistent with proportionally more younger women adopting cigarette smoking despite  
declines in the general population (Centers for Disease Control and Prevention, 2005a; Jemal, 
Ward, & Thun, 2005). 
2.5.2 Screen-detectable Cancer 
At a population level, a temporally circumscribed increase in incidence should result from the 
relatively recent and widespread use of mammographic screening for breast cancer, prostate-
specific antigen (PSA) blood testing for prostate cancer, and endoscopic screening or fecal occult 
blood testing for colorectal cancer. If screening improves survival, then reduced late stage 
incidence and mortality should follow. Reduced cervical cancer incidence and mortality are 
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expected outcomes from Papanicolaou and human papilloma virus (HPV) testing for pre-
malignant cervical dysplasia (National Cancer Institute, 2005a). 
Our APC trend analyses confirmed increases in screen-detectable cancer incidence and 
decreases in mortality. If anything, APC parameter deviation patterns suggested waning 
incidence and mortality pressure from factors possibly affecting recent birth cohorts or recent 
time periods. Declining enthusiasm for cervical and breast cancer screening among certain 
population subgroups may explain recent birth cohort- or time period-specific reductions in 
screen-detectable cancer incidence (H. L. Howe et al., 2006; National Cancer Institute, 2005a). 
Examining results from mathematical models, Berry et al. (Berry et al., 2005) concluded that 
both screening and treatment-related factors are lowering U.S. breast cancer mortality. Other 
factors possibly affecting recent breast cancer trends include changes in hormone therapy use 
(Clarke et al., 2006), xenobiotic estrogen exposures (Clemons & Goss, 2001), and reproductive 
practices. Analysts (Chu, Tarone, & Freeman, 2003; Etzioni et al., 1999) offer conflicting 
opinions regarding the effects of PSA testing on recent prostate cancer mortality trends. 
2.5.3 Cancer Unrelated to Tobacco or Screening 
In 2007, the category created here of cancer unrelated to tobacco or screening is projected to 
include, in men and women, respectively, 27 and 32 percent of all-cancer incidence and 36 and 
36 percent of all-cancer mortality (American Cancer Society, 2007b). Replicating methods used 
by Dinse et al. (Dinse, Umbach, Sasco, Hoel, & Davis, 1999), we also observed a generally 
increasing incidence of cancer unrelated to tobacco or screening. The analysis reported by Dinse 
et al. used 1975-1994 incidence data from the 9-registry SEER program. Adding corrections for 
reporting delay, our analysis used 1979-2003 incidence data, also from the 9-registry SEER 
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program. Relative to the Dinse et al. AAPC findings, we observed lower AAPC estimates in men 
and higher estimates in women, a result that eliminated the previously described gender 
difference with respect to AAPC. 
Recent birth cohorts of women experienced increased pressure on the incidence of cancer 
unrelated to tobacco or screening. For white and black women, some have speculated that this 
phenomenon, appearing after the 1939-1948 birth cohort (Figure 2-1), may be possibly related to 
occupational exposures. According to Toossi (Toossi, 2002), the percentage of adult women 
working outside the home increased from 34 percent in 1950 to 60 percent in 2000. By 2004, 
women comprised 44 percent of the U.S. labor force (United States Office of Personnel 
Management, 2006). Exposures to benzene, chemical solvents, radiation, and pesticides and 
employment in food processing, textile, health case and garment industries have been linked to 
cancer risks in women (Zahm & Blair, 2003). Other work has found that blacks 
disproportionately work in blue-collar jobs, which may place them at higher risk from 
occupational cancers.  In light of these observations, previous notions regarding the occupational 
attributable risk for cancer in women may need revision (Zahm & Blair, 2003). 
Table B-2 (from Davis et al, in press in Biopharmacology, that comes from NCI) indicates that 
much of the decline in overall cancer mortality comes from reductions in cancers related to 
smoking or advances in early detection and treatment for screening-related cancer.  It should be 
noted that the incidence of cancer unrelated to tobacco or screening is increasing against a 
backdrop of declining mortality. Improving treatments for cancers unrelated to tobacco or 
screening may be overcoming the expected effects of increasing incidence on mortality. 
However, if one assumes an average time period trend affecting cancer mortality favorably, 
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results from APC models (time period deviation plots; Figure 2-4) suggest that in recent time 
periods this favorable trend may be attenuating in women. 
Analyses of U.S. NHL trends generally describe increasing incidence, with mortality first 
increasing until the late 1990s and decreasing thereafter, a favorable trend possibly related to 
new treatments for aggressive disease (Hennessy, Hanrahan, & Daly, 2004). Our APC analyses 
also showed generally increasing NHL incidence and mortality, although recent time period 
effects portend (Figures 2-2 and 2-4) lower risks in the future. Explanations for increasing NHL 
incidence have included improved ascertainment, changes in diagnostic practices, infection with 
human immunodeficiency virus (HIV), organ transplantation, and medical immunosuppression 
(Ansell & Armitage, 2005; Grulich, Vajdic, & Cozen, 2007). Environmental factors possibly 
contributing to NHL trends include occupational and agricultural exposures to pesticides, 
solvents, dusts, polychlorinated biphenyls, and bacteria (Band, Le, Fang, & Gallagher, 2004; 
Keller-Byrne, Khuder, Schaub, & McAfee, 1997; Lynge, Anttila, & Hemminki, 1997; Nelson, 
2005; Pearce & Bethwaite, 1992; Rothman et al., 1997; Scherr, Hutchison, & Neiman, 1992; 
Zheng, Blair, Zhang, Weisenburger, & Zahm, 2002). Nevertheless, the continuing increases in 
NHL incidence remain poorly understood and are not likely to be due to improved ascertainment 
alone. 
2.5.4 Methodology Issues 
The use of population-based registries to study cancer incidence trends assumes uniform case 
ascertainment over time. Modeling past experience with delayed cancer case reporting, the SEER 
program has produced correction factors that can be used to adjust current cancer counts for case 
ascertainment expected to occur in the future (Midthune, Fay, Clegg, & Feuer, 2005). Our APC 
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analyses used these correction factors. However, other unrecognized biases in case ascertainment 
may exist such as fads in diagnoses. 
Because it is difficult to examine a large array of age-specific rates, a variety of different 
methods for comparing changes in rates over time have been devised. Averaging disease rates 
across age groups is commonly used to simplify study of disease occurrence over time. However, 
study of age-adjusted rates assumes that time period-related factors that affect risk similarly 
regardless of age. In contrast, the APC model considers age-specific risks to be affected by 
factors related to birth cohort membership, in addition to factors related to calendar time. The 
APC model assumes that age-specific rates are affected equally by birth cohort-specific factors, 
regardless of time period, and equally by time period-specific factors, regardless of birth cohort 
membership. The APC model may fail to detect interesting time-limited factors having unique 
effects on specific age groups. For example, widespread prostate cancer screening started 
suddenly in the late 1980s and early 1990s. Prostate cancer screening was endorsed primarily for 
middle-aged men. As a result, the PSA test introduced a powerful time period effect that would 
not be expected to affect every birth cohort equally, but primarily those cohorts of men in their 
fifties and sixties during the late 1980s and early 1990s. APC models are not designed to detect 
prostate cancer risk effects related to the interaction between age group and time period. 
2.6 CONCLUSION 
In conclusion, APC analyses showed increasing incidence of NHL and cancer unrelated to 
tobacco or screening. Relative to earlier birth cohorts, white women belonging to recent birth 
cohorts may be facing an increased incidence of cancer unrelated tobacco or screening. 
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Determining whether the category of cancer unrelated to tobacco or screening constitutes a valid 
measure of general environmental influences on cancer risk requires more research. 
It should be noted that the category of smoking-related cancers that we employed here 
provides a conservative indication of the impact of smoking on cancer.  While about 85% of all 
lung cancer is believed to be associated with smoking, less than half of all bladder, kidney, 
esophageal and kidney cancer are thought to be smoking-related.  As a result, the estimates 
provided in this exercise will overestimate the impact of smoking and underestimate the impact 
of other avoidable causes of these same tumors.  Thus, occupational epidemiology has identified 
these same sites as elevated in groups employed with solvents, pesticides, and other workplace 
toxic agents. 
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Table 2-1 Results from cancer category-, gender-, and race-specific APC models of 9-registry SEER 1979-
2003 age-specific incidence (thirteen 5-year age groups between 20-24 and 80-84 years), corrected for 
reporting delay 
       Statistical significance1 
Cancer category Gender Race 
Poisson 
model2 AAPC 95% C.I. GR25 
cohort 
parameters 
period 
parameters 
Tobacco-related  Men White Extra -0.92 -1.10, -0.73 0.79 **** ** 
  Black Simple -1.47 -1.87, -1.07 0.69 **** *** 
 Women White Extra 0.83 0.64,  1.02 1.23 **** * 
  Black Extra 0.18 -0.29,  0.66 1.05 ****  
Screen-detectable Men White Extra 2.51 1.93,  3.10 1.86   
  Black3 Extra 3.02 2.22,  3.83 2.11 *  
 Women White Extra 0.37 0.23,  0.50 1.10 **** **** 
  Black Simple 0.10 -0.15,  0.36 1.03 **** ** 
Men White Extra 0.99 0.70,  1.29 1.28  **** 
 Black Extra 0.72 0.28,  1.16 1.20 * *** 
Women White Extra 0.92 0.82,  1.01 1.26 ****  
Unrelated to tobacco 
or screening 
 Black Simple 0.79 0.59,  0.99 1.22 **  
NHL Men White Extra 2.33 1.78,  2.88 1.78  **** 
  Black Extra 3.17 2.28,  4.06 2.18  *** 
 Women White Simple 1.92 1.70,  2.14 1.61  **** 
  Black Simple 3.29 2.53,  4.05 2.24   
AAPC - Average annual percentage change, C.I. - confidence interval, GR25 - 25 year generational risk 
1. p-value: <0.0001****, <0.001***, <0.01**, <0.05* 
2. Poisson model fitted: simple Poisson model or extra-Poisson model 
3. Analysis restricted to twelve 5-year age groups between 25-29 and 80-84 years 
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Table 2-2 Results from cancer category-, gender-, and race-specific APC models of U.S. 1969-2003 age-
specific mortality (thirteen 5-year age groups between 20-24 and 80-84 years) 
       Statistical significance1 
Cancer category Gender Race 
Poisson 
model2 AAPC 95% C.I. GR25 
cohort 
parameters 
period 
parameters 
Tobacco-related  Men White Extra -0.89 -0.98, -0.80 0.80 ****  
  Black Extra -0.92 -1.07, -0.77 0.79 **** **** 
 Women White Extra 0.80 0.68,  0.93 1.22 **** *** 
  Black Extra 0.35 0.15,  0.55 1.09 **** **** 
Screen-detectable Men White Extra -1.10 -1.27, -0.93 0.76   
  Black Extra -0.34 -0.57, -0.11 0.92 ****  
 Women White Extra -1.44 -1.51, -1.36 0.70 **** **** 
  Black Extra -0.83 -0.95, -0.71 0.81 **** **** 
Men White Extra -0.55 -0.61, -0.49 0.87 **** **** 
 Black Extra -0.35 -0.44, -0.26 0.92 **** **** 
Women White Extra -0.80 -0.84, -0.76 0.82 **** **** 
Unrelated to tobacco 
or screening 
 Black Extra -0.68 -0.76, -0.60 0.84 **** **** 
NHL Men White Extra 0.62 0.42,  0.82 1.17 **** **** 
  Black Extra 1.39 1.09,  1.68 1.41  **** 
 Women White Extra 0.28 0.17,  0.40 1.07 **** **** 
  Black Simple 1.54 1.27,  1.80 1.46 **** **** 
AAPC - Average annual percentage change, C.I. - confidence interval, GR25 - 25 year generational risk 
1. p-value: <0.0001****, <0.001***, <0.01**, <0.05* 
2. Poisson model fitted: simple Poisson model or extra-Poisson model 
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        1 The APC analysis of screen-detectable cancer incidence in black men was restricted to twelve 5-year age  
           groups between 25-29 and 80-84 years. 
        2 Cancer unrelated to tobacco or screening. 
Figure 2-1 Results from cancer category-, gender-, and race-specific APC models of 9-registry SEER 1979-
2003 age-specific incidence (thirteen 5-year age groups between 20-24 and 80-84 years), corrected for 
reporting delay; birth cohort-specific deviations added to the linear effect due to birth cohort 
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        1. The APC analysis of screen-detectable cancer incidence in black men was restricted to twelve 5-year age 
groups between 25-29 and 80-84 years. 
        2. Cancer unrelated to tobacco or screening. 
Figure 2-2 Results from cancer category-, gender-, and race-specific APC models of 9-registry SEER 1979-
2003 age-specific incidence (thirteen 5-year age groups between 20-24 and 80-84 years), corrected for 
reporting delay; time period-specific deviations added to the linear effect due to time period 
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     1. Cancer unrelated to tobacco or screening. 
Figure 2-3 Results from cancer category-, gender-, and race-specific APC models of U.S. 1969-2003 age-
specific mortality (thirteen 5-year age groups between 20-24 and 80-84 years); birth cohort-specific deviations 
added to the linear effect due to birth cohort 
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       1. Cancer unrelated to tobacco or screening 
Figure 2-4 Results from cancer category-, gender-, and race-specific APC models of U.S. 1969-2003 age-
specific mortality (thirteen 5-year age groups between 20-24 and 80-84 years); time period-specific deviations 
added to the linear effect due to time period 
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3.1 ABSTRACT 
Objective: Previous analyses of Surveillance Epidemiology and End Results (SEER) data have 
documented striking time-related increases in non-Hodgkin’s lymphoma (NHL) incidence in the 
United States. Using data from the Pennsylvania Cancer Registry (PCR), which is not part of 
SEER, this study evaluated whether patterns of NHL differ in these two areas. Methods: 
Joinpoint and age-period-cohort (APC) regression models were applied to summarize gender- 
and race-specific NHL incidence time trends in Pennsylvania and the SEER registries between 
1985 and 2004. Multiple regression analysis was used to identify demographic factors associated 
with age-adjusted county-specific NHL patterns in Pennsylvania. Results: According to APC 
analyses, Pennsylvania NHL incidence increased, on average, 1.5% and 2.5% annually in white 
and black men and 1.6% and 3.2% annually in white and black women. Average annual increase 
of gender- and race- specific NHL incidence in the SEER registries was similar to the PCR, 
except for white men (0.3% per year). Diffuse lymphoma appeared to be the most important 
contributor to the increase of NHL incidence in PCR and SEER registries. In Pennsylvania, NHL 
incidence was higher in counties with a greater percentage of urban residents (p=0.005). 
Conclusion: Though not identical, NHL incidence patterns in Pennsylvania and the SEER 
registries were generally parallel. The ecologic association observed in Pennsylvania NHL 
incidence and urban residence may be relevant to NHL patterns in the entire United States. 
Future work should explore what aspects of urbanization may account for the association with 
increased NHL risk. 
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3.2 INTRODUCTION 
While the incidence of all cancers combined started to decrease in 1992 in the United States, 
non-Hodgkin’s lymphoma (NHL) incidence rates have continued to demonstrate substantial 
increases for men and women since 1975 (H. L. Howe et al., 2006).  With an estimated 63,190 
new cases and 18,660 deaths projected for the year 2007, NHL is the fifth most common 
malignant neoplasm among men and women in the United States (American Cancer Society, 
2007b). NHL occurrence has increased dramatically and internationally over the past few 
decades. Studies have shown that NHL incidence increased in Canada (Liu, Semenciw, & Mao, 
2003), Australia (Grulich & Vajdic, 2005), Sweden, Denmark and  Finland (Sandin et al., 2006) 
and other countries in Europe (Adamson et al., 2007). Increases in NHL incidence were also 
observed on a smaller scale within state cancer registries. Among Pennsylvania residents, 3330 
new cases and 1140 deaths from NHL are expected for the year 2007. Based on the report from 
Pennsylvania Department of Health, in 1999-2003, the age-adjusted NHL incidence rates in 
Pennsylvania (24.5 per 100,000 in men and 17.0 per 100,000 in women) were slightly higher 
than rates in the United States (22.6 per 100,000 in men and 16.0 per 100,000 in women) 
(American Cancer Society, 2007b). Between 1994 and 2003, annual age-adjusted incidence was 
increasing among white and black men and women in Pennsylvania (Pennsylvania Department 
of Health, 2004).  
Reasons for the rise in NHL incidence are not fully understood. Regardless of histologic 
subtypes, the impact of changes in case ascertainment, classification and diagnostic practice on 
overall NHL incidence trends is thought to be small (Clarke et al., 2004). NHL risk has been 
related to altered immunity, especially Human Immunodeficiency Virus (HIV) infection or 
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acquired immunodeficiency syndrome (AIDS) (Grulich, Vajdic, & Cozen, 2007). NHL cases are 
also attributed to certain environmental exposures, such as pesticides and solvents (Boffetta & de 
Vocht, 2007; Hartge & Smith, 2007). Phenoxy herbicide and 2,4-Dichlorophenoxyacetic acid 
(2,4-D), two widely utilized agricultural chemicals, have been consistently associated with 
higher NHL risk (Fisher & Fisher, 2004). Research has indicated that the causes for NHL vary 
according to histologic subtypes (Groves, Linet, Travis, & Devesa, 2000). It was documented 
that the distributions of NHL incidence by major subtypes varied across geographical regions 
related to host, racial, and environmental differences (Muller, Ihorst, Mertelsmann, & 
Engelhardt, 2005). Given the uncertainty of NHL etiology, researchers continue to investigate 
possible external causes of NHL, including environmental and occupational exposures.  
To generate possible etiologic hypotheses, it is relevant and important to learn whether 
patterns of NHL occurrence observed in a nationwide cancer registry (Surveillance 
Epidemiology and End Results, SEER) agree with those observed in a statewide cancer registry. 
This study describes NHL time trends in the Pennsylvania Cancer Registry (PCR) and in the 
SEER registries by characterizing gender- and race-specific NHL incidence associated with age, 
calendar year, birth cohort, and histologic subtype. An ecologic analysis is performed to 
determine variables associated with county-specific NHL incidence in Pennsylvania. 
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3.3 MATERIALS AND METHODS 
3.3.1 Data Sources 
Information on newly diagnosed NHL cases in Pennsylvania from 1985 to 2004 was based on 
PCR data obtained from the Pennsylvania Department of Health. With the University of 
Pittsburgh Institutional Review Board exempting the study from review, we requested 
anonymous patient ID, along with gender, race, age at diagnosis, year of diagnosis, primary site, 
ICD-O-3 histology code, and individual FIPS county codes from the PCR Expanded Incidence 
File (EIF). PCR used the rules from SEER to determine multiple primaries. PCR converted ICD-
O and ICD-O-2 to ICD-O-3 and used ICD-O-3 histology codes to recode the NHL cases. We 
used SEER*Prep software (version 2.3.5) (National Cancer Institute, 2006b) to convert case-
level data in EIF to the SEER*Stat (version 6.3) database format (National Cancer Institute, 
2007c), allowing data analysis by using SEER*Stat software. Using SEER*Stat, NHL cases and 
population counts were aggregated into 5-year age groups (thirteen groups from 20-24 to 80-84 
years of age) and 5-year time periods (four groups from 1985-1989 to 2000-2004) according to 
gender and race (white and black). Each incidence rate was expressed as the number of cancers 
per 100,000 persons at risk and was age-adjusted relative to the U.S. 2000 standard population. 
Similar to the classification used by Groves et al. (Groves, Linet, Travis, & Devesa, 2000), NHL 
subtypes were classified according to the Working Formulation (WF), which was developed for 
prognostic purposes. We categorized NHL ICD-O-3 codes into six major subtypes: small 
lymphocytic NHL, follicular NHL, diffuse NHL, high-grade NHL, peripheral T-cell NHL, and 
NHL not otherwise specified (NOS). Information on newly diagnosed NHL cases in the U.S. 
was obtained from SEER*Stat (National Cancer Institute, 2006c) and analyses similar to PCR 
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data were conducted. We selected NHL data based on SEER 9 registries, which include states of 
Connecticut, Hawaii, Iowa, New Mexico, Utah, metropolitan areas of Atlanta, Detroit, San 
Francisco-Oakland, and 13 counties of Seattle-Puget Sound. The coverage includes 9.5% of the 
total U.S. population and does not include Pennsylvania or any cities in Pennsylvania. 
Adjustment for reporting delay in cancer trend analyses could correct underreported 
cancer cases especially for persons diagnosed in recent years. To adjust current cancer cases 
accounting for delayed reports, delay-adjusted  models produced by the National Cancer Institute 
(NCI) were used to correct cancer case counts in the SEER registries (National Cancer Institute, 
2007a). In conformity with PCR regulations, the EIF we received excluded cancer reports from 
non-Pennsylvania cancer registries and federal (Department of Veterans Affairs, VA) medical 
care facilities. The PCR continually updates the EIF to include all available information. The EIF 
includes delayed reports, cancer reports received after publication of PCR annual cancer 
incidence and mortality summaries (Pennsylvania Department of Health, 2007). Comparing 
calendar year-, gender-, and race-specific NHL incidence counts in our restricted PCR EIF with 
incidence counts calculated and published annually (Pennsylvania Department of Health, 2007), 
we estimated correction factors that accounted for out-of-state or VA reporting and delayed 
reporting. Estimating correction factors of Pennsylvania reporting delays and out-of-state reports 
could diminish the magnitude of underestimation of recent NHL cases in cancer trend analysis.  
Pennsylvania county population estimates were obtained from a publicly available 
internet resource (National Cancer Institute, 2006a) to estimate age-adjusted county-specific 
NHL incidence. County-specific U.S. 1990 and 2000 census estimates, including the percentage 
of white population, the number of males per 100 females, the percentage of employed civilians 
aged 16 years and over who work in the farming, fishing and forestry industries, and the 
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percentage of the population living in urban areas, were retrieved and averaged (United States 
Buerau of Census). We obtained cumulative cases of acquired immune deficiency syndrome 
(AIDS, not including human immunodeficiency virus (HIV) infection without AIDS) in 
Pennsylvania from 1980 to 2004 by county of residence from the Pennsylvania Department of 
Health (Pennsylvania Department of Health, 2005). Average annual AIDS incidence was 
calculated according to county-specific cumulative cases and population size.  
3.3.2 Data Analysis 
We modeled age-adjusted NHL incidence (corrected for delayed reports) in the Pennsylvania and 
SEER registries using joinpoint regression (National Cancer Institute. Statistical Research and 
Applications Branch, 2005) to describe long-term time trends for gender and race subgroups. 
This approach uses weighted least squares regression to fit multiple line segments, with 
unspecified join points, to the data on a log scale (Kim, Fay, Feuer, & Midthune, 2000). The 
program can determine the necessary number of joinpoints and their locations, and thus can 
assess whether trends in incidence rates have changed over time.  
Using SAS software (version 9.1, SAS Institute Inc., Cary, NC, USA), we conducted age-
period-cohort (APC) analyses to characterize gender- and race-specific NHL incidence in terms 
of temporal patterns associated with age, time period, and birth cohort. Using 5-year age and 
period intervals for each combination of race and gender, APC analysis was based on the 
methods reported by Dinse et al. (Dinse, Umbach, Sasco, Hoel, & Davis, 1999). An extra-
Poisson model was fitted to account for the excess variation if a Poisson model did not fit well as 
judged by a 0.05-level chi-square goodness-of-fit test. We summed linear effects due to time 
period and birth cohort to form the drift (D), which represents long-term changes in cancer rates 
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over time. Cohort and period deviations from linearity were plotted to indicate departures from a 
trend line due to effects of birth cohort or time period. We estimated the Average Annual 
Percentage Change (AAPC) based on 5-year time intervals, where AAPC = 100* [exp (D/5)-1] 
and exp indicates an antilog. The generational risk represented as GR25, is the relative risk of 
cancer incidence in one generation versus the previous generation. Assuming that a generation 
spans 25 years, we estimated the 25-year generational risk by GR25 = [exp (D/5)]25.  
We used county-specific NHL incidence in the 67 Pennsylvania counties to examine 
NHL geographic patterns between 1985 and 2004. Using GeoDa (version 0.95i) software, we 
created a shapefile by combining NHL data with Pennsylvania county Cartographic Boundary 
Files (United States Census Bureau, 2001). Gender-specific quartile maps (box maps, which 
focus on highlighting outliers in the data) were constructed to summarize the distribution of NHL 
incidence across the 67 counties. Multiple linear regression by the method of  ordinary least 
squares was performed using SPSS software (version 12.0.1, SPSS Inc., Chicago, IL, USA) to 
evaluate whether county variations of race, gender, occupation, urbanization, and AIDS 
incidence associated with Pennsylvania county-specific NHL incidence between 1985 and 2004 
time period.  
3.4 RESULTS 
According to joinpoint analysis, similar but not identical patterns of gender- and race-specific 
NHL age-adjusted incidence (corrected for delayed reports) were observed in Pennsylvania and 
the SEER registries (Figure 3-1). In Pennsylvania, NHL incidence was highest in white men, 
with a 2.6% estimated annual percentage change (EAPC) between 1985 and 1997 and a smaller 
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increase since 1997. Estimated NHL incidence among SEER white men rose 2.1 % annually 
from 1987 to 1995, leveled off between 1995 and 1998, and started to increase 1.1% annually in 
most recent years. NHL incidence in Pennsylvania black men rose aggressively, with a 7.4% 
increase per year during 1985-1994, and appeared to decrease slightly since 1994. In the SEER 
registries, NHL incidence in black men erupted in the late-1980s (EAPC=7.8%), began to level 
off in 1994, and peaked between 2002 and 2004. Female NHL incidence rates increased 
overtime from 1985 to 2004 (EAPC was 2.0% in white women and 2.6% in black women in 
Pennsylvania; EAPC was 1.5% in white women and 2.4% in black women in the SEER 
registries). However, NHL incidence rate was higher in white women than in black women. In 
Figure 3-2, age-specific incidence rates showed temporal increases among white men and 
women ages 65 years and older. Among white men younger than 45 years-old, NHL incidence 
appeared to be higher in SEER registries than in Pennsylvania. SEER white men younger than 55 
years-old have experienced a decreasing pattern of NHL incidence since 1990-1994, except for 
the youngest age group. NHL incidence was decreasing consistently across the age groups in 
Pennsylvania white men.   
APC model estimates of long-term increases in NHL incidence, 1985-2004, were given 
by the average annual percentage change (AAPC): 1.6% and 2.5% for white and black men, and 
1.6% and 3.2% for white and black women in Pennsylvania, compared to 0.3% and 2.2% for 
white and black men, and 1.4% and 3.2% for white and black women in the SEER registries 
(Table 3-1). The generational risk (GR25) indicated that the four gender-race subgroups in 
Pennsylvania have between 49% and 119% greater risks of developing NHL than did the 
previous generation, compared to 9%-117% in the SEER registry. NHL incidence among 
Pennsylvania and SEER white men exhibits deviations from linearity due to birth cohort. In the 
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SEER registries, time period parameters significantly (p<0.05) improved the fit of APC models 
for NHL incidence in men and white women. Deviation added to linear effects has shown a 
downward sloping over recent birth cohorts and time periods among Pennsylvania and SEER 
white and black men (Figure 3-3) 
In Pennsylvania, estimated incidence of small lymphocytic, follicular, and diffuse NHL 
was highest in white men, whereas high-grade NHL incidence was highest in black men 
(Appendix Table B-3). Estimated incidence of follicular NHL was higher in whites than in 
blacks, whereas the incidence of peripheral T-cell NHL was higher in blacks than in whites. 
Incidence of diffuse lymphoma was the highest among NHL subtypes and the rate increased 
overtime across Pennsylvania and SEER registries (Figure 3-4). In Pennsylvania, for two races 
combined, incidence of diffuse lymphoma has increased 2.8% annually in men and 2.7% 
annually in women between 1985 and 2004. Incidence of follicular and peripheral T-cell 
lymphoma has increased over time among men and women. Incidence of small lymphocytic 
lymphoma appeared to be stable during the study period. Incidence of high-grade NHL and not 
otherwise specified NHL has decreased in the 1990s. In the SEER registries, patterns of NHL 
incidence by subtype are similar to those in Pennsylvania.  
In Pennsylvania, age-adjusted NHL incidence appeared to be higher in counties located 
in central areas (Appendix Figure B-5). According to multivariate regression analysis (Table 3-
2), counties with higher percentages of residents living in urban areas had higher NHL incidence 
rates. Estimated NHL incidence was not associated with percentage of whites, ratio of males per 
100 females, percentage of adults working in the farming, fishing and forestry industries, and 
AIDS incidence between 1980 and 2004.  
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3.5 DISCUSSION 
Remarkable changes in NHL incidence in Pennsylvania and the SEER registries have been 
demonstrated. Overall, APC analyses confirmed the substantial increase of NHL incidence in the 
past two decades. Constant increase of NHL incidence was observed in women and in older age 
groups. In addition, estimated incidence of diffuse and follicular lymphoma has increased 
overtime. However, in the SEER registries, recent increase of NHL incidence in white men is 
unexplained. A striking increase in black men in 2002 may due to variation of case ascertainment. 
Further data including case ascertainment and population variation are needed to identify the 
pattern.  
NHL is one of the major AIDS-associated malignancies highly impacted by the AIDS 
epidemic in the U.S. (Engels et al., 2006). In Pennsylvania, annual AIDS incidence increased 
rapidly since 1982 and started to level off in 1995. AIDS incidence was highest among people 
aged 30-49, and 79% of AIDS cases were males (Pennsylvania Department of Health, 2005). 
Featuring birth cohort and time period effects, APC analyses estimated a slowing NHL epidemic 
in Pennsylvania and SEER white and black men, an observation which is consistent with the 
decreased HIV/AIDS epidemic and improved treatment in the 1990s. Nevertheless, AIDS 
epidemic could not explain NHL patterns in women or elderly. Higher NHL incidence rate has 
been associated with altered immunity, including transplantation, blood transfusion, and 
immunosupression (Chow & Holly, 2002; Fisher & Fisher, 2004). (Grulich, Vajdic, & Cozen, 
2007). Infectious agents, such as Epstein-Barr virus (EBV) are being regarded as established 
causes of NHL, especially in individuals with immune dysfunction (Engels, 2007) However, 
how these factors contribute to the NHL time trend are either unknown or thought to be small. 
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NHL cases are often attributed to uncertain environmental exposures. Relationship 
between occupational benzene exposure and NHL has been suggested (Goldstein & Witz, 1999; 
M. T. Smith, Jones, & Smith, 2007; Vineis, Miligi, & Costantini, 2007). Exposures to 
agricultural chemicals and solvents are associated with increased NHL risk (De Roos et al., 2003; 
Fritschi et al., 2005; Hardell & Eriksson, 1999; Rafnsson, 2006; Schroeder et al., 2001). 
According to data from National Agriculture Statistics Services, central Pennsylvania has the 
most acres of farmland in the state (United States Department of Agriculture, 2007). In 
Pennsylvania, counties located in central areas appear to have higher NHL incidence. Study on 
farming activity in central Pennsylvania should be considered to identify whether application of 
agricultural chemicals is related to NHL risks. 
The study indicated that NHL risk differs by gender. Continuously increased NHL 
incidence among women is unexplained. Use of hair dyes among women has been associated 
with NHL development but the evidence is controversial (Takkouche, Etminan, & Montes-
Martinez, 2005). Increased female workforce and occupational exposure in recent decades may 
be contributing. Study on the relationship between environmental exposures and gender-specific 
NHL incidence, especially among older groups with long-term exposure could provide directions 
of NHL etiology study.  
Regarding NHL histologic subgroups, diffuse and follicular lymphoma appeared to be the 
main contributor of increased NHL incidence in Pennsylvania and the SEER registries. 
Occurrence of NHL subtypes may vary by risk factors. Industrial workers exposed to 
electromagnetic field and metals have been related to development of diffuse lymphoma (Band, 
Le, Fang, & Gallagher, 2004; Zheng, Blair, Zhang, Weisenburger, & Zahm, 2002). It has been 
suggested that exposures to agriculture chemicals exert stronger effects on diffuse and follicular 
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lymphoma (Band, Le, Fang, & Gallagher, 2004; Fritschi et al., 2005). In the United States, total 
pesticide use rose from 647 million pounds in 1964 to 1144 million pounds in 1979 and then 
declined to 971 million pound in 1995 (United States Environmental Protection Agency, 1997). 
The role of occupation and pesticide exposure in the increase of diffuse and follicular lymphoma 
obliges further evaluation. Lifestyle including diet, obesity, and physical activity has drawn 
attention to subtype NHL etiology (Chang et al., 2006; Chang et al., 2005; Kelemen et al., 2006; 
Zheng et al., 2004). Obesity-related NHL risk increase is greater for diffuse and follicular 
subtypes (Pan, Mao, Ugnat, & Canadian Cancer Registries Epidemiology Research, 2005; 
Skibola et al., 2004). In Pennsylvania, 16% of adults were obese in 1995 and it rose to 25 % in 
2005 (Pennsylvania Department of Health, 2006a). The emerging obesity epidemic may 
contribute to the increasing incidence of NHL. Studies of the association between obesity, diet, 
and lymphoma subtype are warranted to confirm the associations. 
High-grade NHL, a subtype related to 90% of AIDS-related NHL, was the most rapidly 
increasing subtype in 1978-1995, particularly among men (Groves, Linet, Travis, & Devesa, 
2000). In recent years, observation of decreased high-grade NHL in Pennsylvania and SEER 
registries may reflect the decline of AIDS epidemic. Recent decrease of not otherwise specified 
NHL may due to improved histologic diagnosis of lymphoma. Findings from our population-
based study provide evidence that the distribution of NHL subtypes differs in demographic 
patterns and incidence trends. Although changing classifications of NHL histologic subtypes and 
improved diagnosis may misclassify NHL histologic subtypes, future investigations should 
evaluate NHL risks according to subtype, as defined by histology and classification criteria. 
In Pennsylvania, populations living in urbanized counties have been found to have higher 
NHL incidence. Devesa et al has found that incidence of NHL was lower in rural areas (Devesa 
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& Fears, 1992; Muller, Ihorst, Mertelsmann, & Engelhardt, 2005). Although interpreting the 
ecologic relationship between urbanization and increased NHL risk is limited, disparity of 
urbanization might be relevant to NHL risk in the entire US. Percent of total population living in 
urban area has increased 23% from 1950 to 2000 (64% in 1950 and 79% in 2000) (United States 
Bureau of Census). Characteristics of urban living, such as population density and structure, 
lifestyle, development process and socioeconomic factors, should be studied to identify potential 
NHL risk factors and to account for NHL geographic distributions in Pennsylvania. 
3.6 CONCLUSION 
Although the time course of NHL occurrence is not well explained, increased NHL incidence 
patterns observed in Pennsylvania generally paralleled with those observed in the SEER 
registries. Analyzing cancer data within Pennsylvania have provided insights of NHL epidemic 
and helped to identify candidacy of NHL etiologic factors. In conclusion, gender-specific risk 
factors should be investigated to explain continuous increase of NHL among women. 
Environmental exposure and changes of lifestyle provide clues of NHL etiologic study by 
evaluating patterns of histologic NHL subgroups. Future work should explore what factors and 
aspects of urbanization may account for association with increased NHL occurrence.  
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Pennsylvania  SEER Registry 
 
Figure 3-1 Joinpoint estimates of NHL incidence in the Pennsylvania and SEER registry by gender and race 
for persons diagnosed from 1985 to 2004 at ages 20 to 84, adjusted for age and reporting delays 
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Figure 3-2 NHL incidence (Log-Scale) in the Pennsylvania (PA) and SEER registry by age group and 
time period for white men and women diagnosed from 1985 to 2004 at ages 20 to 84, adjusted for 
reporting delays.  The X’s are observed values and the lines are predicted values based on an age-
period-cohort model with 5-year age and period interval
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Table 3-1 Results from separate age-period-cohort models for NHL incidence in the Pennsylvania and SEER 
registry by gender and race for persons diagnosed from 1985 to 2004 at ages 20 to 84, adjusted for reporting 
delays.  The APC analyses used 5-year age and period intervals 
 
 
       Significance level [1] 
Registry Gender Race 
Poisson 
model fits AAPC 95% C.I. GR25 
cohort 
curvature 
period 
curvature 
PCR Men White Yes 1.55 1.16, 1.94 1.47 0.0189* 0.4477 
  Black No 2.49 1.02, 3.99 1.85 0.4719 0.1199 
 Women White Yes 1.61 1.18, 2.05 1.49 0.1969 0.1165 
  Black Yes 3.18 1.77, 4.61 2.19 0.7114 0.9596 
SEER  Men White No 0.33 -0.23, 0.89 1.09 0.0159* 0.0077** 
  Black No 2.23 1.20, 3.27 1.74 0.4131 0.0005*** 
 Women White Yes 1.42 1.17, 1.67 1.42 0.1476 0.0262* 
  Black No 3.15 2.05, 4.26 2.17 0.4660 0.4485 
PCR – Pennsylvania Cancer Registry 
AAPC - Average annual percentage change, C.I. - confidence interval, GR25 - 25 year generational risk 
[1] <0.001***, <0.01**, <0.05* 
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Figure 3-3 Cohort and period deviations from linearity as estimated from separate age-
period-cohort models for NHL incidence in the Pennsylvania and SEER registry in men by 
race e for persons diagnosed from 1985 to 2004 at ages 20 to 84, adjusted for reporting delays 
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Figure 3-4 Joinpoint estimates of NHL incidence in the Pennsylvania and SEER 9 registries by gender, year 
of diagnosis, and histologic subtype of the Working Formulation (WF) classification for white and black 
combined diagnosed from 1985 to 2004 at ages 20 to 84, age adjusted to the 2000 U.S. standard population
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Table 3-2 Results from multiple linear regression analysis for assessing which factors are important 
predictors of NHL incidence in Pennsylvania among persons diagnosed from 1985 to 2004 at ages 20 to 
84, adjusted for age 
Independent variables Coefficient Std. Error t-statistic P-value 
Constant -4.899 17.718 -0.277 0.783 
White (%) 0.223 0.165 1.351 0.182 
Men/100Women 0.022 0.029 0.751 0.456 
FarmOccupPop (%) 0.108 0.448 0.241 0.811 
Population in Urban (%) 0.070 0.024 2.950 0.005 
AIDS Incidence2  0.190 0.187 1.020 0.312 
1. R-squared from regression model equals 0.22.  
2. AIDS incidence was calculated on the basis of county-specific accumulated AIDS cases and population 
sizes, 1980-2004 
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4.1 ABSTRACT 
Objective: Long-term exposure to arsenic in drinking water has been related to multiple types of 
cancers. The long latency of cancer has challenged arsenic-related cancer research. This ecologic 
study evaluates the relationship between arsenic level in ground water and cancer incidence in 
Idaho. Method: Using cancer incidence data, 1990-2005, from the Cancer Data Registry of 
Idaho and arsenic data from the Idaho Department of Environmental Quality, we conducted 
spatial analysis to identify geographic patterns in incidence for cancers of the bladder, kidney, 
liver, lung, non-Hodgkin’s lymphoma (NHL), and all sites combined. Spatial regression was 
applied to evaluate the relationship between arsenic level in ground water and cancer incidence. 
Results: Spatial clustering of lung cancer incidence was demonstrated in males and females. 
Incidence for kidney cancer and all sites combined was spatially clustered in females but not in 
males. Higher incidence for lung cancer and all cancer sites combined were clustered in north 
Idaho, while lower rates clustered in southeastern Idaho. No relationship was found between 
arsenic level in ground water and cancer incidence. However, smoking prevalence is 
significantly associated with cancer incidence for bladder, kidney, lung, and all sites combined. 
Conclusion: Exposure to arsenic in ground water is not associated with cancer incidence in 
Idaho. Although this study was not able to identify other environmental risks, smoking is 
contributing to excess cancer occurrence among Idaho counties. To clarify relationship between 
arsenic exposure and cancer risk, individual risk assessment adjusted for smoking and 
occupation is crucial in southwest counties where ground water has been found to contain 
relatively higher levels of arsenic. 
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4.2 INTRODUCTION 
Arsenic is a metalloid found in water, soil, and air from natural sources and anthropogenic 
activities such as mining and agriculture applications. Arsenic is also used to manufacture 
agricultural products such as insecticides, herbicides, and fungicides (ASTDR, 1993). 
Populations exposed to arsenic from geologic contaminated water are found around the world, 
including locations in Taiwan, Chile, Mexico, Argentina, Bangladesh, and the United States 
(Kapaj, Peterson, Liber, & Bhattacharya, 2006; Marshall et al., 2007; Tapio & Grosche, 2006; 
Yoshida, Yamauchi, & Fan Sun, 2004). These studies have also demonstrated that arsenic 
exposure is associated with chronic health effects including cancer of the bladder, lung, liver, 
kidney, and skin. However, the latency of arsenic-related cancer may be as high as 50 years. The 
mode of arsenic action may relate to oxidative stress, altered DNA methylation, altered DNA 
repair, enhanced cell proliferation, gene amplification, and chromosomal abnormalities (Huang, 
Ke, Costa, & Shi, 2004; Hughes, 2002; Kitchin, 2001). Limitations on the individual exposure 
assessment and potential confounders hamper the etiologic research on arsenic-related cancer 
risk (Chappell et al., 1997; Gebel, 2000). In 2001, after considering the analyses and risk 
assessment on arsenic from National Research Council (NRC), the United States Environmental 
Protection Agency (EPA) lowered the maximum contaminant level (MCL) for arsenic in 
drinking water from 50 μg/l to 10 μg/l (United States Environmental Protection Agency, 2001). 
The change of MCL for arsenic in drinking water and cancer risks associated with arsenic 
exposures, particularly at relatively lower exposure levels in the United States population, has 
generated discussion and debate.  
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In order to provide an understanding of water-quality conditions and how they may vary 
locally, regionally, and nationally, the United States Geological Survey (USGS) has collected 
and analyzed several contaminants, including arsenic, in potable water from 18,850 wells in 595 
counties across the United States since the 1970s. In 24 percent of the counties where data were 
available, at least 10% of the samples had arsenic concentration exceeding 10 µg/l. According to 
the geographic map that USGS developed, widespread and elevated arsenic concentrations in the 
United States were found in the northeast, west and the midwest, including the state of Idaho 
(Welch, A.Watkins, Helsel, & Focazio, 2000). Ground water samples from the Idaho Statewide 
Ambient Ground Water Quality Monitoring Program have been analyzed for arsenic since 1990. 
Approximately 15 percent of the 1,900 statewide monitored sites have arsenic concentration 
exceeding the MCL of 10 µg/L (Hagan, 2004; Neely, 2002). Ground water in southwest and 
south central Idaho has the highest density of arsenic concentrations that exceed the MCL. Since 
95% of the population relies on ground water as a source of drinking water, arsenic has become a 
concern for many ground water users in Idaho. Recently, geographic information system (GIS) 
technology has been applied to analyze the geographic distribution of causative agents and their 
relationships to health outcomes in exposed populations. Applying GIS technology, this ecologic 
study examines the spatial patterns of county-specific cancer incidence in Idaho and evaluates 
the relationship between arsenic level in ground water and cancer incidence in Idaho.  
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4.3 MATERIALS AND METHODS 
4.3.1 Data Collection 
The Idaho Department of Water Resources (IDWR) provided 6,019 arsenic concentration 
measurements (range 0-950 µg/l) for approximately 1,900 Idaho ground water sources (wells and 
springs) sampled during summer months between 1990 and 2005. Laboratory analysis of arsenic 
in ground water is based on IDWR standard operating procedures according to EPA 
recommended methods for drinking water contaminants (EPA 200.9) (Neely, 2002). County 
rankings based on calendar year-specific arsenic concentration measurements were similar from 
year to year (data not shown). Therefore, for each of the 44 counties in Idaho, we averaged 
arsenic concentration values over all water sources and time points to estimate personal arsenic 
exposures for county residents. The number of measurements by county ranged between 35 
(Camas County) and 570 (Canyon County). According to the IDWR (Neely, 2002), two-thirds of 
sampled ground water sources are designated for domestic use.  
We requested county- and gender-specific newly diagnosed cases for all ages combined, 
from 1990 to 2005, for cancer of the bladder, kidney and renal pelvis, liver and bile duct, lung 
and bronchus, non-Hodgkin’s lymphoma (NHL), and all sites combined from Cancer Data 
Registry of Idaho (CDRI). We obtained data aggregated in 5-year intervals from 1990 to 2004 
and an overall data aggregated from 1990 to 2005. Reporting of cases was based on county of 
residence at the time of diagnosis. The cancer rates were age adjusted to the U.S. 2000 standard 
population. County-specific smoking prevalence and the percentage of population classified as 
not obese (body mass index (BMI) < 25) were retrieved from Geographic Report by CDRI, 
which is based on the Behavioral Risk Factor Surveillance System (BRFSS), 1997-2005. 
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Overall, 44,872 respondents were identified from BRFSS in the State of Idaho. Data were 
weighted by probability of selection, and poststratified to 2004 Idaho population estimates by 
age group, sex, and county. A minimum of 30 respondents was required to generate county-level 
statistics (Cancer Data Registry of Idaho, 2006). County-level demographic data on percentage 
of white population, number of males per 100 females, and population density per square mile of 
land area were retrieved from 2000 U.S. census summary files (United States Bureau of Census, 
2005). Power calculation is indicated in Appendix C.  
We also grouped Idaho counties into three categories according to arsenic concentration 
in ground water sources: low arsenic county (≤2μg/l, n=23), intermediate arsenic county (2-
9µg/l, n=16), and high arsenic county (≥10 µg/l, n=5). Gender and cancer site-specific incidence 
was calculated by these three groups. Confidence interval is 95% for incidence rate. 
4.3.2 Spatial Autocorrelation Analysis 
Using ArcGIS software (ESRI, Redlands CA, version 9.1), we created a shapefile, a digital 
vector format for storing geometric location and associated attribute information, by combining 
cancer data and independent variables with the Idaho county map from the US census 2000 
Cartographic Boundary Files (United States Bureau of Census, 2001). The shapefile was 
imported into GeoDa (University of Illinois, Urbana, IL, version 0.95i), a free program which 
provides a graphical interface for methods of descriptive spatial data analysis, to conduct spatial 
analysis for four different time period: 1990-1994, 1995-1999, 2000-2004, and 1990-2005. 
Based on the categorized incidence rates, quartile box maps, focused on highlighting outliers in 
the data, were constructed to check the cancer distribution of 44 counties between 1990 and 
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2005. An outlier was defined as any value that lies above 1.5 times of interquartile range (the 
difference in value between the 75% and 25% observation) added to the 75th percentile or below 
1.5 times the interquartile range subtracted from the 25th percentile. Using Empirical Bayes 
Smoothing procedure to remove the effect of the varying population across the counties, we 
constructed smoothed quartile maps.  
Contiguity weights file was first created to define neighbors based on queen contiguity 
which classifies areas as neighbors even if their borders only touch each other (Anselin, 2005). 
Global spatial autocorrelation analysis with queen-weighted matrix was used for testing 
clustering of age-adjusted cancer incidence in Idaho counties by gender and time period. In the 
global spatial autocorrelation test, Moran’s I is the correlation value in a location that is 
calculated by the spatially weighted average of the neighboring values. Similar to the correlation 
coefficient, the values of Moran’s I range from +1 meaning positive spatial autocorrelation 
(clustering) to -1 indicating negative spatial autocorrelation (dispersed); with values close to 0 
indicating a random pattern (Moran, 1950). Local Indicator Spatial Autocorrelation (LISA) was 
used to test clusters of age-adjusted cancer incidence in Idaho counties by gender and time 
periods. Five scenarios may emerge in a LISA cluster map: (1) locations with high values and 
similar neighbors: high-high, (2) locations with low values and similar neighbors: low-low, (3) 
locations with high values and low value neighbors: high-low, (4) locations with low values and 
high-value neighbors: low-high, and (5) locations with no significant local autocorrelation 
(Anselin, 2005).  
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4.3.3 Spatial Regression Analysis 
Using a queen-weighted matrix file, ordinary least squares regression was first performed to 
evaluate the spatial dependence in the model. County was used as the geographic unit and age-
adjusted cancer incidence was the dependent variable. Arsenic levels, percentage of white 
population, number of men per 100 women, population density on land, percentage of current 
smokers, and percentage of residents with a BMI less than 25 were included in the regression 
model as covariates. Spatial lag and spatial error are two types of spatial dependence that were 
considered in this study. Spatial lag is caused by the autocorrelation present in the variables that 
are not included in the model. Spatial error is due to the autocorrelation present in the dependent 
variable. In the regression output of spatial autocorrelation diagnostics, Lagrange Multiplier 
(LM-lag) tests for a missing spatially lagged dependent variable were used in the linear models. 
Lagrange Multiplier (LM-error) tests for spatial error dependence were also used in the linear 
models. If neither LM-Lag nor LM-Error statistics rejected the null hypothesis, indicating no 
spatial lag or spatial error in the model; results from the ordinary least squares (OLS) model was 
selected for interpretation. The selection of spatial regression model is based on the rules 
documented in the Workbook of GeoDa (Anselin, 2005).  
4.4  RESULTS 
County average arsenic levels in ground water are highest in southwest Idaho (Figure 4-1). The 
counties of Owyhee, Washington, Twin Fall, Payette, and Canyon have relatively higher 
percentages of samples containing arsenic levels higher than 10 μg/l (64%, 56%, 49%, 38% and 
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37%, respectively, data not shown). Compared to SEER program, gender-specific cancer 
incidence for lung, liver and all sites combined in males and females is significantly lower in 
Idaho (Table 4-1). In Figure 4-2, box maps indicate that northern and western Idaho has a higher 
incidence for bladder, kidney, liver, and lung cancer, and for cancer in all sites combined. 
Counties in southeast Idaho have a lower incidence for cancer of the bladder, liver, lung, and all 
sites combined. NHL incidence is higher in Idaho’s central and southern counties. Empirical 
Bayes smoothed maps show that no outliers were observed in Idaho county-specific cancer 
incidence, although more counties located in northern and central Idaho fall into the third and 
forth quartile in each cancer site (map not shown).  
Female county-specific incidence rates for kidney cancer and for all sites combined 
showed significant (p<0.05) spatial autocorrelation (Figure 4-3). Incidence for lung cancer has 
the highest Moran’s I statistics: 0.42 in males and 0.57 in females. The LISA cluster map 
illustrates the significant locations by coloring different types of spatial autocorrelation. Shown 
in Figure 4-3, high-high clusters of cancer incidence for all sites combined in females were 
identified in five northern counties. In males, counties in southeast Idaho had a lower bladder 
cancer incidence surrounding counties that had similar bladder cancer incidence. Low-low 
cluster of cancer incidence for all sites combined were also found in males and females. In 
males, significant high-high clusters of kidney cancer incidence were found in Kootenai County 
and Boise County. In both genders, higher incidence for lung cancer was clustered in northern 
Idaho and lower incidence for lung cancer was clustered in southeastern Idaho. No specific 
patterns were observed in incidence for liver cancer. Butte, Madison, Bonneville and 
Washington Counties had higher NHL incidence and were surrounded by counties with higher 
NHL incidence (Figure 4-3). Cancer incidence for all sites combined was spatially autocorrelated 
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in males and females from 1990 to 1994, and in females from 1995 to 1999 (Table 4-2). Spatial 
clustering of lung cancer incidence was observed with a highest Moran’s I value in both genders 
from 1990-1994 to 2000-2004, except for males between 1995 and 1999.  
Gender-specific Pearson correlation coefficient is presented in Table 4-3. No relationship 
was found between arsenic exposure in ground water and cancer risk in Idaho; however, 
incidence for lung cancer had the highest correlation coefficient. For males, compared to the 
rates in the low arsenic counties, the intermediate and high arsenic counties have significantly 
higher incidence for all sites combined and lung cancer (Table 4-4). Among females, cancer 
incidence for all sites combined, lung and bladder cancer was higher in the intermediate arsenic 
counties compared to the low arsenic counties. Based on spatial regression analysis, ordinary 
least squares (OLS) estimation was selected for cancer of the bladder, kidney, liver, NHL, and all 
sites combined. According to maximum likelihood estimation, the spatial lag model was selected 
for lung cancer (Table 4-5 and Appendix Table B-4). Between 1990 and 2005, cancer incidence 
was not associated with arsenic level in ground water and population density on land. Higher 
prevalence of current smokers was associated with higher incidence for cancer of the bladder, 
kidney, lung, and all sites combined. Incidence for kidney cancer was higher among counties 
having a higher proportion of white residents. Increased incidence for liver cancer was associated 
with a higher proportion of male residents and a higher proportion of population with higher 
BMI value (Table 4-5). Figure 4-4 demonstrates that smoking prevalence was higher in counties 
located in northern and southwestern Idaho, while counties in eastern Idaho had a lower smoking 
prevalence (Moran’s I=0.34, p=0.004).  
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4.5 DISCUSSION 
In Idaho, lower incidence for cancer of bladder, lung, and all sites combined was observed in the 
eastern area, a similar result to the IDCR reports (Christopher J.  Johnson & Carson, 2000). No 
evidence was found that arsenic levels in ground water is associated with cancer incidence for 
bladder, kidney, liver, lung, NHL, and all sites combined in Idaho. Smoking is significantly 
attributed to the occurrence for cancer of the bladder, kidney, and lung, and all sites combined in 
Idaho residents. Patterns of smoking prevalence may account for the clustering in cancer 
incidence, especially lung cancer. Some of the information presented on cancer risk, including 
ethnicity, gender and obesity may also account for multiple causes of cancer in Idaho. 
The role of arsenic in developing cancer has been studied. Due to the long latency of 
arsenic-related carcinogenesis, historically considered to be 30-50 years, ecologic studies on the 
relationship between arsenic exposure and cancer risk were strong and consistent only in the 
areas with high arsenic exposures. In southwest Taiwan, where arsenic in drinking water was as 
high as 600 μg/l, a dose-response effect was observed between arsenic-contaminated well water 
and age-adjusted mortality rates (1973-1986) for cancer of the bladder, kidney, skin, and lung in 
both genders (Wu, Kuo, Hwang, & Chen, 1989). Similar results were found in Cordoba, 
Argentina (Hopenhayn-Rich, Biggs, & Smith, 1998) and in Chile (Marshall et al., 2007; A. H. 
Smith, Goycolea, Haque, & Biggs, 1998). However, results from ecologic studies on cancer risk 
among populations exposed to lower arsenic level were controversial (Ayotte et al., 2006; Lamm 
et al., 2004; Lewis, Southwick, Ouellet-Hellstrom, Rench, & Calderon, 1999). In Idaho counties, 
average arsenic level in ground water is lower than 50 μg/l, ranging from 0.09 μg/l in Lewis 
County to 43.06 μg/l in Washington County. Moreover, only four counties have an average 
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arsenic level higher than 10 μg/l. It is difficult to identify exposure-disease associations in areas 
of generally low-level arsenic exposure. Similarly, Johnson and Mitchell recently evaluated the 
relationship between arsenic level in ground water and cancer incidence in Idaho. Adjusting for 
county-level cancer risk factors, no evidence links Idaho cancer incidence to arsenic exposure at 
the ZIP code level (Christopher J. Johnson & Mitchell, 2007). 
Other US-based epidemiologic studies have been conducted in Utah (Bates, Smith, & 
Cantor, 1995), in the western Nevada and California (Steinmaus, Yuan, Bates, & Smith, 2003) 
and in New Hampshire (Karagas et al., 2004). Overall, these case-control studies have failed to 
demonstrate a direct relationship between arsenic exposure in drinking water and cancer risk in 
nonsmokers. However, increased cancer risk was observed among smokers. In Idaho, arsenic 
levels in ground water and smoking prevalence are both higher in northern and southwestern 
counties, whereas cancer incidence is higher. The interaction between smoking and arsenic 
genotoxicity and whether smoking may induce arsenic-related cancer should be further explored.  
It has been reported that arsenic exposure is associated with increased incidence for non-
leukemia childhood cancer, including bone cancer in 5-14 year-old children and lymphomas in 
14-19 year-old young adults (Moore, Lu, & Smith, 2002). Arsenic carcinogenicity may vary by 
susceptibility in populations. We used cancer incidence of all ages combined to link cancer risk 
and arsenic exposure. Age-specific incidence rates would be helpful to identify arsenic-related 
cancer risk in vulnerable subgroups. Considering potential environmental caner risk in Idaho, the 
extent of radiation release from the Idaho National Laboratory (INL) and the exposure to public 
has been regarded. The INL is on the upper Snake River Plain that spans Butte, Bingham, 
Bonneville, Clark, and Jefferson Counties (Centers for Disease Control and Prevention, 2005b). 
Although no excess cancer mortality risk was observed in counties with nuclear facilities 
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(Forman et al., 1987; G. R. Howe, 1991), we have identified that higher NHL incidence clustered 
in Butte County and Bonneville County. Specific question regarding radiation exposure and 
NHL risk should be discussed. 
Although exposure status and health outcomes are unknown among individuals, this 
ecologic-based study preliminarily evaluated suspected arsenic-related cancer risks in Idaho. 
Spatial analysis has confirmed that smoking contributes to cancer risks of the bladder, kidney, 
and lung. However, several limitations and biases can be raised. Because of the long latency of 
cancer and contemporary of exposure and cancer data, we have assumed that the exposure 
estimates and the demographic data in the 1990s and 2000s could provide indication of past 
exposures. Secondly, ecologic fallacy has limited the generalizability of interpretation. Averaged 
county-specific arsenic level could not capture a precise exposure for Idaho residents and lead 
results toward null. Calculating county-specific arsenic level in ground water by weighting site-
specific utilizing population could provide better estimations for arsenic exposure. In addition, 
using residence at time of cancer diagnosis might not account for migration variation and 
misclassification could occur.  
Cancer is a disease with multiple causes, looking only at arsenic in water may be a 
limited indicator of total carcinogenetic exposures. Arsenic toxicity could be altered by nutrients 
like selenium and zinc or water co-contaminants like antimony, which either suppress or enhance 
in vivo genotoxicity and carcinogenicity (Gebel, 2000). Arsenic toxicity also depends on 
exposure route and dose, frequency and duration, as well as on individual susceptibilities 
(Tchounwou, Centeno, & Patlolla, 2004), which are difficult to measure as a whole. Recently, a 
space-time information system was introduced which enables visualization and analysis of 
space-time data to assess individual lifetime exposure to inorganic arsenic (Meliker et al., 2007). 
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It’s flexibility accounts for a number of combinations of parameters, including water and food 
consumption, residential and occupational histories, temporal changes in the magnitude and 
location of exposure, life-course for susceptibility changes across years and age. The space-time 
information system may be a useful tool for exposure and risk assessment compared to 
conventional GIS technologies. 
4.6 CONCLUSION 
In Idaho, geographic disparity of arsenic-contaminated ground water might not explain spatial 
patterns of cancer incidence. We validated that smoking has contributed critical proportions to 
cancer occurrence among Idaho residents. We also demonstrated the usefulness of GIS 
techniques on the epidemiological study. However, this study was not able to evaluate the role of 
occupational risks or of other environmental risk factors. Smoking only partly explains spatial 
patterns of cancer incidence in Idaho. Other environmental exposures should also be considered. 
Although arsenic levels in ground water is not shown to be related to cancer incidence in Idaho, 
the proportion of cancer cases attributable to arsenic exposure is not conclusive. Concerning 
populations exposed to relatively high arsenic-contaminated ground water in southwestern Idaho, 
conducting an individual-based study, adopting better tools on arsenic exposure assessment, and 
adjusting for smoking and other potential confounders would help to identify arsenic-related 
cancer risk in this population. 
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Figure 4-1 County average arsenic concentration in ground water, data was 
based on the Idaho Statewide Program, 1991-2004. Individual points identify 
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Table 4-1 Idaho and SEER 9 registries all cancer and selected cancer gender and site-specific incidence rates 
for person diagnosed between 1990 and 2004 (age-adjusted U.S. 2000 standard) 
  Men 
 Idaho SEER 9 Registries 
Cancer site Rate1 SE LCI UCI Rate SE LCI UCI 
All Malignant Cancers 534.8* 2.7 529.6 540.1 581.4 0.6 580.2 582.6 
Lung and Bronchus 73.4* 1.0 71.5 75.4 86.8 0.2 86.3 87.3 
Urinary Bladder      37.8    0.7 36.4 39.3 37.3 0.2 37.0 37.6 
Kidney and Renal Pelvis 14.6* 0.4 13.8 15.5 16.2 0.1 16.0 16.4 
Liver and bile duct 3.9* 0.2 3.5 4.4 8.0 0.1 7.8 8.1 
Non-Hodgkin Lymphoma 20.6* 0.5 19.5 21.6 24.0 0.1 23.8 24.3 
  Women 
 Idaho SEER 9 Registries 
Cancer site Rate SE LCI UCI Rate SE LCI UCI 
All Malignant Cancers 389.3* 2.1 385.2 393.4 417.3 0.5 416.4 418.2 
Lung and Bronchus 42.8* 0.7 41.4 44.2 50.8 0.2 50.5 51.1 
Urinary Bladder 8.4* 0.3 7.8 9.0 9.5 0.1 9.4 9.7 
Kidney and Renal Pelvis        8.1 0.3 7.6 8.8 8.1 0.1 8.0 8.2 
Liver and bile duct 1.9* 0.1 1.7 2.3 2.9 0 2.9 3.0 
Non-Hodgkin Lymphoma      16.0 0.4 15.2 16.9 15.9 0.1 15.7 16.1 
1. Rates are per 100,000 and age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) 
standard; CI: Confidence intervals (Tawari mod) are 95% for rates 
* Incidence rate is significantly different from Idaho relative to SEER 9 registries  
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Figure 4-2 Box maps for cancer incidence in the Idaho cancer registry by gender and cancer site, for person 
diagnosed between 1990 and 2005, adjusted for age 
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Figure 4-3 Cluster maps for cancer incidence in the Idaho cancer registry by gender and cancer site, for 
person diagnosed between 1990 and 2005, adjusted for age
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Table 4-2 Moran’s I value for cancer incidence in the Idaho cancer registry by gender and 
cancer site, for person diagnosed between 1990 and 2004, adjusted for age 
  Males Females 
Cancer Site Year Moran's I p-value Moran's I p-value 
All cancer combined 1990-1994 0.205 0.024 0.226 0.008 
 1995-1999 0.035 0.274 0.239 0.004 
 2000-2004 0.108 0.086 0.113 0.104 
Bladder  1990-1994 0.015 0.308 0.026 0.266 
 1995-1999 0.018 0.348 -0.070 0.258 
 2000-2004 0.132 0.042 -0.095 0.220 
Kidney & Renal Pelvis  1990-1994 0.058 0.112 -0.034 0.496 
 1995-1999 -0.119 0.168 -0.011 0.622 
 2000-2004 -0.088 0.250 0.220 0.028 
Liver & Bile Duct 1990-1994 -0.137 0.090 -0.019 0.542 
 1995-1999 -0.109 0.080 -0.006 0.594 
 2000-2004 -0.008 0.634 0.059 0.218 
Lung & Bronchus 1990-1994 0.326 0.004 0.512 0.002 
 1995-1999 0.070 0.174 0.397 0.002 
 2000-2004 0.394 0.004 0.312 0.002 
NHL 1990-1994 0.132 0.078 -0.121 0.146 
 1995-1999 -0.107 0.180 -0.076 0.316 
 2000-2004 0.048 0.206 0.114 0.060 
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Table 4-3  Pearson Correlation coefficient for arsenic level in ground water and cancer 
incidence by gender and cancer site, for persons diagnosed from 1990 to 2005, adjusted for 
age 
 All cases Male Female 
 β p-value β p-value β p-value 
All cancer sites 0.04 0.823 0.05 0.733 0.02 0.909 
Bladder  -0.02 0.909 0.03 0.859 -0.01 0.963 
Kidney 0.02 0.895 -0.10 0.513 0.15 0.339 
Liver 0.06 0.684 -0.08 0.611 0.22 0.160 
Lung 0.25 0.101 0.28 0.061 0.20 0.184 
NHL 0.09 0.555 0.06 0.719 0.10 0.532 
Data was analyzed by SPSS 12.1 
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Table 4-4 Idaho all cancer, and selected cancer site-specific incidence rates, by sex and county grouping 
according to arsenic ground water levels for person diagnosis between 1990 and 2004 
    
Low Arsenic Counties 
 
(≤ 2μg/L, N=23) 
Intermediate Arsenic 
Counties  
(2-9μg/L, N=16)  
High Arsenic Counties  
 
(≥ 10μg/L, N=5) 
    Rate1 LCI UCI Rate1 LCI UCI Rate1 LCI UCI 
Men and Women          
Average population 354,970 640,588 220,728 
All Malignant Cancers 422.7 417.0 428.5 457.8 453.3 462.3 440.7 433.5 448.0 
Lung and Bronchus 50.2 48.2 52.2 57.7 56.1 59.4 58.3 55.7 61.0 
Urinary Bladder 19.7 18.5 21.0 22.4 21.4 23.5 20.4 18.9 22.0 
Kidney and Renal Pelvis 10.5 9.6 11.4 11.8 11.1 12.6 10.3 9.2 11.4 
Liver and Intrahepatic Bile Duct 2.3 1.9 2.7 3.0 2.7 3.4 3.3 2.7 4.0 
Non-Hodgkin Lymphoma 17.7 16.5 18.9 18.0 17.1 18.9 18.3 16.9 19.8 
           
Men           
Average population 178,496 320,441 109,298 
All Malignant Cancers 500.9 491.6 510.4 537.7 530.3 545.1 529.9 518.1 541.9 
Lung and Bronchus 65.0 61.7 68.4 74.0 71.2 76.8 80.0 75.5 84.8 
Urinary Bladder 35.2 32.7 37.8 39.3 37.2 41.4 37.2 34.1 40.5 
Kidney and Renal Pelvis 13.6 12.1 15.2 15.7 14.4 16.9 13.1 11.3 15.1 
Liver and Intrahepatic Bile Duct 3.2 2.5 4.0 4.0 3.4 4.6 4.8 3.7 6.1 
Non-Hodgkin Lymphoma 19.0 17.3 20.9 20.8 19.4 22.3 21.0 18.7 23.5 
           
Women           
Average population 176,474 320,146 111,430 
All Malignant Cancers 364.9 357.6 372.4 400.0 394.3 405.8 376.8 367.7 386.2 
Lung and Bronchus 38.3 36.0 40.8 45.2 43.2 47.2 41.5 38.6 44.7 
Urinary Bladder 7.2 6.2 8.3 9.2 8.4 10.1 7.6 6.4 9.0 
Kidney and Renal Pelvis 7.8 6.8 9.0 8.5 7.6 9.3 7.8 6.5 9.2 
Liver and Intrahepatic Bile Duct 1.5 1.1 2.1 2.1 1.7 2.6 2.0 1.4 2.7 
Non-Hodgkin Lymphoma 16.6 15.0 18.2 15.6 14.5 16.8 16.1 14.3 18.1 
Rates are per 100,000 and age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) 
standard; Confidence intervals are 95% for rates (Tawari mod) 
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Table 4-5 Results from spatial regression analysis for assessing predictors of cancer incidence in Idaho 
among persons diagnosed from 1990 to 2005, adjusted for age 
 
 
 
 
 
 
 All sites 1 Bladder 1 
Kidney & Renal 
Pelvis 1 
R-square 0.396 0.243 0.394 
Independent variable β p-value β p-value β p-value 
Arsenic (ug/ml) -0.227 0.858 0.005 0.970 0.014 0.848 
White (%)* 1.914 0.240 0.114 0.464 0.245 0.014 
Men/Women (%)* 1.718 0.334 0.232 0.178 0.111 0.291 
Population Density/Land* 0.308 0.065 0.005 0.737 0.014 0.159 
Current Smoker (%) 6.939 0.004 0.545 0.017 0.330 0.018 
BMI<25 (%) -0.992 0.598 0.164 0.367 -0.097 0.385 
 
Liver &  
Bile Duct 1 
Lung &  
Bronchus 2 NHL 1 
R-square 0.239 0.641 0.078 
Independent variable β p-value β p-value β p-value 
Arsenic (ug/ml) 0.016 0.658 0.203 0.471 0.045 0.706 
White (%)* 0.072 0.123 -0.462 0.186 0.013 0.933 
Men/Women (%)* 0.114 0.030 0.155 0.685 0.165 0.319 
Population Density/Land* 0.007 0.141 0.010 0.784 0.012 0.427 
Current Smoker (%) -0.021 0.748 0.226 <0.001 -0.217 0.309 
BMI<25 (%) -0.122 0.028 0.067 0.871 -0.260 0.142 
1. Ordinary least squares estimation 
2. Spatial lag model- Maximum likelihood estimation 
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.
Figure 4-4 Quartile map, box map, and LISA cluster map for Idaho county smoking prevalence, Behavior 
Risk Factor Surveillance System (BRFSS), 1997-2005 
Quartile Map Box Map LISA cluster map 
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5.0  DISCUSSION AND CONCLUSION 
William Farr, one of the progenitors of epidemiology, advocated that medical statistics should be 
carefully studied, because these provide important clues about underlying causes of population 
health.   His death in 1883 was lauded in the Lancet for his pioneering work laying the statistical 
tools that are the foundation of public health knowledge.  This dissertation has avoided the florid 
writing of Farr, but is consistent with his notion that the trend is all we can examine:  all else is 
conjecture. This three-part dissertation evaluates patterns of cancer at the national and state level, 
in an effort to clarify the current burden of cancer and to promote the development of etiologic 
hypotheses about avoidable cancer causes. The first part evaluates national patterns of cancer for 
various groupings of the disease for the past quarter century.  The second part conducts an 
assessment of age-specific patterns of NHL in the State of Pennsylvania, compares these with the 
U.S. overall, and speculates about some possible underlying causes; and the third part carries out 
an exploratory Geographic Information System study employing cancer incidence data 
aggregated at the county level and arsenic levels reported in groundwater in the State of Idaho.   
Cancer is a disease of multiple causes and stages. As a result the temporal and spatial 
analysis of national and state patterns of cancer cannot pinpoint specific causes.  But, such 
analysis can form the backbone upon which to base future research and, under some 
circumstances where demographic, environmental and behavioral information are available, can 
also clarify the impact of cancer control policies.  
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Many studies have been conducted to identify cancer pathology, to understand cancer 
occurrence, and to propose and evaluate better cancer detection and treatment. The analysis of 
temporal and spatial patterns of cancer remains a complex and challenging enterprise that has 
recently been neglected.  The purposes of the three related but independent reports presented in 
this dissertation are to increase awareness of available medical, environmental and demographic 
data in population-based state and national cancer registries, to provide innovative examples of 
modeling cancer data analysis that takes advantage of new developments in statistical thinking 
and Geographic Information Systems approaches, and to stimulate the need for additional 
research regarding environmental and other avoidable cancer risks.  
According to our analysis, in the U.S., for the past quarter century, tobacco-related cancer 
incidence declined among men and increased among women. During this same time period, 
screen-detectable cancer incidence (breast, prostate, colon-rectal and cervix) increased, more 
rapidly among men than women. For the category of cancer that we created that was unrelated to 
tobacco or screening,  incidence increased in four gender-race groups.  Throughout this time 
period, the growth in, NHL--a cancer classified as unrelated to tobacco or screening-- has been 
strong and consistent in all groups nationwide.  In the State of Pennsylvania, NHL incidence 
increases paralleled those of the nation in every gender-race group. The diffuse lymphoma 
histologic subgroup appeared to be the most important contributor to the NHL increase. NHL 
incidence was higher in Pennsylvania counties with a greater percentage of urban residents. In 
Idaho, using state of the art tools of Geographic Information System analyses, we found that 
county average arsenic levels in ground water are highest in southwestern counties. Incidence for 
lung cancer and all cancers combined was spatially clustered in men and women, with higher 
incidence clustered in northern Idaho and lower rates clustered in southeastern Idaho.  Smoking 
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prevalence contributes to higher incidence for cancer of the bladder, kidney, lung, and all sites 
combined.  No association was found between arsenic levels in ground water and cancer 
incidence in Idaho.  We were not able, within the constraints of this analysis, to examine other 
potential causes of these geo-spatial variations in cancer in Idaho. 
The cancer trends noted here indicate major shifts in the types of cancer in the U.S. 
within the past two decades. For men, smoking-related cancers have declined, while screening-
detected and cancers not related to smoking or screening has increased.  For women, smoking-
related cancers generally increased, although the increase may be attenuating, and screening-
detected and cancers not related smoking or screening have also increased.  Improved diagnosis 
and access to health care certainly play a role in the reported increases; however, they should not 
be assumed to account completely for these trends. Evaluating time trends by gender may avoid 
diagnostic artifacts since it is not likely that diagnosis would substantially vary with gender over 
the years. The appropriate degree of aggregating or disaggregating cancer data has been 
discussed (Bailar, 1990). The categories used will reflect the purposes of the analysis.  Studying 
cancer mortality by combing cancer sites is useful for assessing overall progress on cancer 
prevention and treatment.  Many cancer cases are preventable. Early diagnosis and improved 
treatment for breast and colon-rectal cancer (and childhood cancer, not considered here) have 
been shown to reduce deaths.  
The evaluation of time trends of specific types of cancer can be useful, as these can 
suggest hypotheses for future research regarding underlying causes. We have confirmed the 
nationwide decline in cancer deaths in recent decades, but also indicated some important trends 
in various groupings of cancer that merit serious examination.  In addition, it should be noted 
that the overall decrease is not shared equally across subgroups within the population. As had 
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been widely reported, African Americans tend to fare more poorly at every stage of cancer, even 
adjusted for access to care.  Whether these differences may be related to their differential 
workplace and residential exposures to degraded environments are a matter that should be 
explored systematically in future work. Ethnic disparity, health accessibility, or effectiveness of 
public health practice should be carefully inspected to determine their contribution to these 
disparities and propose policy interventions to ameliorate them. Determining why incidence for 
cancers not linked to smoking or screening is increasing, while all sites combined cancer 
incidence is decreasing, presents an important and challenging question for cancer researchers 
and public policy makers. 
At this point, we cannot determine the proportional contribution to increased risk of 
cancer that stems from changes in lifestyle, medical practice, environmental carcinogens (i.e. 
contaminated drinking water or polluted air), occupational hazards (i.e. organic solvents, 
asbestos, or pesticides), and medical or background radiation (i.e. radon).  These exposures, 
which concentrate in certain subgroups of the population, are involuntary but, to a large extent, 
avoidable, and often are completely beyond an individual’s control or knowledge. As a cohort, 
the generation born in the middle of the twentieth century experienced several factors that could 
have increased their cancer risk compared to those born at the turn of that century, including 
newly introduced pesticides and other industrial materials and poor control of occupational 
carcinogens (Davis, Hoel, Fox, & Lopez, 1990) Estimating a relative cancer rate in ever-smokers 
versus never-smokers for different time points of interest would be more helpful in 
demonstrating a role for other environmental cancer causes not attributable to smoking.   
Cancer registries provide data and serve as resources for conducting epidemiologic 
studies within large populations. It should be understood that there are clear limits to this work, 
 93 
because the data on which it is based do not reflect the heterogeneity of the American 
population. Although routinely collected statistics on cancer occurrence are commonly reported 
among racial and ethnic populations, the SEER population is predominantly white, and the black 
population is primarily urban. The white population is represented well in each of the SEER 
areas but this is not true for blacks. Approximately 77% of the black population in SEER is 
represented by the metropolitan areas of Atlanta (34%), Detroit (33%), and San Francisco (13%) 
(National Cancer Institue (SEER)). The system does not include any estimates of cancer in black, 
rural-poor populations, especially in the southern part of the country, nor does it include urban 
African Americans in parts of the south, excepting Atlanta. Estimates of the number of cancer 
cases in black, rural-poor populations based on SEER incidence rates is not reflective of the 
cancer experience in these populations. As a result, interpretation of racial differences based on 
this study cannot be generalized to all populations in the United States.  
In addition, quality of cancer case ascertainment has been a concern, although the U.S. 
maintains one of the highest quality cancer registries in the world. Changes of ICD-O coding 
regulation and changes in detection practices may affect records of diagnostic stage and 
histologic subtypes of cancer. However, the SEER program sets the standard for data quality 
worldwide. Quality control has been an integral part of the SEER Program activities since its 
inception in 1973 (National Cancer Institute, 2005c), and histopathologic confirmation rate has 
always been above 90% and close to 100% in recent years. Case ascertainment from PCR 
follows the definitions and manual used by the National Cancer Institute’s SEER program 
(Pennsylvania Department of Health, 2006b). Although concerns of variation associated with the 
small number of events can occur when using county statistics, the data are comparable between 
PCR and SEER.  
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Meanwhile, data from population-based cancer registries, supplemented by linkage with 
administrative databases, are important and accessible resources for monitoring potential causes 
of cancer, or say, environmental epidemiologic/ecologic study. Taking Project #3 as an example, 
by linking cancer incidence from CDRI with arsenic levels in ground water monitored by Idaho 
Department of Environmental Quality, we evaluated the relationship between arsenic exposure in 
ground water and cancer risk. Although we cannot identify personal arsenic-related cancer risk, 
nor prove causal relationship, the study emphasizes the importance of smoking factors and other 
environmental exposures. Moreover, cancer is a disease with long latencies. We are aware that 
exposure estimates and demographic data that we obtained for Idaho are nearly contemporaneous 
with cancer data and that does not allow for the consideration of latency. Therefore, we assumed 
that the exposure estimates can provide some indication of past exposures that may have 
occurred decades earlier. Existing data has limited our ability to prove this assumption. 
Following the trail of environmental monitoring programs in the coming decades, the cohort data 
could provide refined causative relationships regarding environmental exposures and cancer 
outcomes that account for the long latency of cancer. 
Efforts to project future cancer patterns and evaluate past ones are of vital importance for 
three major reasons.  First of all, these projections will be critical to providing fair policies to 
provide care for the fastest growing segment of many industrial populations that is age sixty and 
older in whom most cancer can be expected to arise.   Second, these analyses can highlight the 
often unappreciated value of national and state registries of cancer statistics and stimulate the 
development of novel statistical models to explore these registries more fully.  Finally, this work, 
also lays the foundation upon which additional research can be based to propose, identify and 
evaluate underlying causes of the patterns and trends we have found. This study utilized existing 
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data to design a complex series of cancer trend modeling activities that provides an important 
addition to the literature and to public health inquiry.  As resources to conduct epidemiologic 
studies remain limited, the importance of devising inventive approaches to existing data systems 
is clear.  This dissertation affirms the value and importance of conducting analyses of descriptive 
data and sets the stage for additional research to be done in the U.S. and internationally on the 
patterns we have described here.  As a concluding point, I anticipate this work will help to 
generate hypotheses on cancer etiology with regard to environmental and other avoidable causes 
of cancer; as well as assist public health officials to effectively plan services, prioritize health 
resource allocations, and develop and measure prevention and intervention strategies.  
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APPENDIX A 
STATISTICAL APPENDIX FOR PROJECT#1 
Consider the following age-period-cohort (APC) model with Nage age-specific rates in each of 
Nper time periods, 
kjiijk C  P  A  )ln(R ++ + =α  + εijk,  (1) 
where Rijk is the rate (cancer incidence or mortality) in the ith age group (indexed 
between 1 and Nage) during the jth time period (indexed between 1 and Nper) for the kth birth 
cohort (indexed between 1 and Ncoh). The εijk are error terms. The model includes an intercept (α) 
and separate terms for age group (Ai), time period (Pj), and birth cohort (Ck). Note, k = Nage – i + 
j and Ncoh = Nage – 1 + Nper, where Ncoh is the number of distinct birth cohorts specified by the 
model. 
For example, separately for each combination of gender, race, and cancer category, we fit 
an APC model to 91 age-specific cancer mortality rates (13 age-specific rates in each of 7 five-
year time periods). Not including the intercept, a typical APC model would be fit against these 
91 age-specific rates through use of 39 parameters, 13, 7, and 19 parameters for age, time period, 
and birth cohort, respectively. However, because of the interdependency of age, calendar time, 
and birth cohort (as given by k = Nage – i + j), not all parameters can be uniquely estimated. 
To handle this problem, Dinse et al. (Dinse, Umbach, Sasco, Hoel, & Davis, 1999) 
parameterized the APC model, as follows, 
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where the βalin, βplin, βclin, age 1Nage−β , 
per
1Nper −β , and 
coh
1Ncoh−β  are model parameters. 
age
1 - N,N ageageH , 
per
1 - N,N perperH , 
and coh 1 - N,N cohcohH  are orthogonal Holford matrices (Holford, 1983). A bolded notation signifies a 
matrix or vector, with dimensions indicated as subscripts. Equations 2-4 effectively decompose 
the APC model (equation 1) into two components. The first component uses three parameters to 
represent linear effects due to age group (βalin), time period (βplin), and birth cohort (βclin). The 
second component specifies age group-specific ( agei
1m
age
m
age
im D=∑
=
1-Nage
H β ), time period-specific 
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H
1m
per
j
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jm Dβ ), and birth cohort-specific ( cohk
1m
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m
coh
km D=∑
=
1-Ncoh
H β ) deviations added to the 
linear effects due to age group, time period, and birth cohort, respectively. 
Although the three parameters representing the linear effects due to age group, time 
period, and birth cohort are not uniquely estimable, it has been shown that certain functions of 
any two of these parameters are uniquely estimable (Holford, 1983). We chose to define a 
uniquely estimable drift parameter driftD  as the sum of βplin and βclin, the linear effects due to time 
period and birth cohort, respectively. The drift parameter can be conceived as the linear effect on 
the natural logarithm of any age-specific rate (cancer incidence or mortality) associated with one 
time period increment, in the absence of any linear effects due to birth cohort. Or, equivalently, 
the drift parameter can be conceived as the linear effect associated with one birth cohort 
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increment, in the absence of any linear effects due to time period. These two examples represent 
the two extreme situations bounding an infinite number of possibilities. In general, the AAPC 
represents the age-independent relative change in cancer risk associated with a temporal change 
of 1 year in duration. 
With respect to deviations added to the linear effects, equations 2-4 specify Nage–1, Nper–
1, and Ncoh–1 uniquely estimable parameters relevant to age group, time period, and birth cohort, 
respectively. Our APC models of age-specific cancer mortality, for example, defined 12, 6, and 
18 deviations relevant to age group, time period, and birth cohort, respectively. Unfortunately, 
the individual parameters, age 1Nage−β , 
per
1Nper −β , and 
coh
1Ncoh−β , and the deviations, 
age
age 1N −D , 
per
per 1N −D , and 
coh
coh 1N −D , calculated with these parameters, lack direct or meaningful interpretation. However, the 
predicted risks at two time periods j and j΄, j ≠ j΄, for two age groups, i and i΄, belonging to the 
same birth cohort, are related, as follows, where i΄ = i + (j΄ – j). 
( )perjperjplinjjii
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Equation 6 enables a direct interpretation of 
per
j
per
j DDe −′ , the exponentiated difference 
between any two time period parameter deviations. The value 
per
j
per
j DDe −′ can be interpreted as the 
cohort-independent (k fixed) risk at time period j΄ relative to time period j, adjusted for both age 
( iie AA −′ ) and the relative risk increase ( plinjje β)( −′ ) expected from the linear effect due to time 
period. The value 
per
j
per
j DDe −′  can be uniquely estimated and interpreted, even though plineβ  is 
unknowable. 
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For presentation purposes, we chose to plot the time period deviations perjD  as a function 
of time period j. The time period parameter deviation change from time period j to time period 
j+1 can be visualized as the slope of the plot between times j and j+1. The exponentiated value of 
this slope can be interpreted as a birth cohort-independent time period-specific factor multiplied 
against plineβ  (the unknowable and constant linear effect from each time period increment) to 
estimate age-adjusted risk at time j+1 relative to time j. Regions of positive and negative slope 
can be viewed to cover sequential time periods exerting positive and negative pressure, 
respectively, on disease risk. Here, positive and negative pressure refers to generally undesired 
and desired trends, respectively, that serve to increase and decrease disease risks. Therefore, 
from a public health perspective, we desire time period deviations showing progressive decrease 
over the most recent time periods. 
The same formulation described above can be used to guide the interpretation of plots of 
birth cohort parameter deviations vs. birth cohort. The exponentiated value of the birth cohort 
parameter deviation change from birth cohort k to birth cohort k+1 can be interpreted as a time 
period-independent birth cohort-specific factor multiplied against clineβ  (the unknowable and 
constant linear effect from each birth cohort increment) to estimate age-adjusted risk in birth 
cohort k+1 relative to birth cohort k. Regions of positive and negative slope can be viewed to 
cover sequential birth cohorts experiencing positive and negative pressure, respectively, on 
disease risk. From a public health perspective, we desire birth cohort deviations showing 
progressive decrease over the most recent birth cohorts. 
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APPENDIX B 
SUPPLEMENTAL TABLES AND FIGURES  
Table B-1 Results from cancer category-, gender-, and race-specific APC models of 9-registry 
SEER 1979-2003 age-specific incidence (thirteen 5-year age groups between 20-24 and 80-84 years), 
not adjusted and adjusted for reporting delay 
   Annual average percent change (AAPC) 
Cancer category Gender Race Not adjusted 
Delay 
adjusted Difference 
Men White -0.98 -0.92 0.06 
 Black -1.53 -1.47 0.06 
Women White 0.76 0.83 0.07 
Tobacco-related  
 Black 0.11 0.18 0.07 
Men White 2.44 2.51 0.07 
 Black1 2.95 3.02 0.07 
Women White 0.30 0.37 0.07 
Screen-detectable 
 Black 0.04 0.10 0.06 
Men White 0.88 0.99 0.11 
 Black 0.59 0.72 0.13 
Women White 0.80 0.92 0.12 
Unrelated to tobacco or 
screening 
 Black 0.66 0.79 0.13 
Men White 2.16 2.33 0.17 
 Black 2.99 3.17 0.18 
Women White 1.74 1.92 0.18 
NHL 
 Black 3.10 3.29 0.19 
1. Analysis restricted to twelve 5-year age groups between 25-29 and 80-84 years 
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Table B-2  Summary of changes in cancer and mortality, 1950-2001 and 5-year relative survival rates, 1950-
2001: men and women, by primary cancer site 
All Races Whites 
Percent Change 1950 - 2001c 
Incidenced U.S. Mortalityb 
5-Year Relative 
Survival Rates 
(Percent)e 
Primary Site 
Estimated 
Cancer 
Cases 
in 2001a 
Actual 
Cancer 
Deaths 
in 2001b Total APC Total APC 1950-54 1995-00 
Oral Cavity and Pharynx 30,100  7,701 -33 -0.5 -48.9 -1.2 46 60.9 
Esophagus 13,200 12,529 21.2 0.7 27.2 0.6 4 15.8 
Stomach 21,700 12,319 -75.8 2.2 -84 -3.5 12 21.5 
Colon and Rectum 135,400 56,887 17.5 0.1 -40.9 -1 37 64.1 
     Colon 98,200 17,860 38.2 0.4 -28.6 -0.6 41 63.1 
     Rectum 37,200 9,027 -16.7 -0.5 -68.7 -2.6 40 64.6 
Liver and Intrahep 16,200 16,952 234.3 2.5 27.4 0.6 1 8 
Pancreas 29,200 29,802 35.9 0.3 21.2 0.1 1 4.2 
Larynx 10,000 3,797 17.8 0 -25.8 -0.5 52 67.4 
Lung and Bronchus 169,500 156,380 290.1 2.2 265.4 2.2 6 15.4 
     Males 90,700 90,660 203.5 1.2 197.5 1.6 5 13.7 
     Females 78,800 65,720 685 4.2 608.1 4.3 9 17.4 
Melanoma of the Skin 51,400 7,542 690.2 4.3 165.6 1.7 49 90.7 
Breast (Females) 192,200 41,394 90 1.5 -22.2 -0.3 60 88.9 
Cervix uteri 12,900 4,092 77.7 -2.3 -79.5 -3.5 59 74 
Corpus and Uterus, NOS 38,300 6,783 14.9 -0.2 -68 -2 72 86.1 
Ovary 23,400 14,800 2.6 0.1 3.8 -0.2 30 44 
Prostate 198,100 30,719 286.2 3.3 8.8 0.3 43 100 
Testis  7,200 335 143.4 2.1 73.3 3 57 96.2 
Urinary Bladder 54,300 12,538 97.1 1.2 31.6 -0.9 53 82.7 
Kidney and Renal Pelvis  30,800 12,372 181.7 2.1 42.8 0.7 34 63.9 
Brain and Other Nervous 17,200 12,609 135.6 1.3 54.9 0.8 21 32.2 
Thyroid  19,500 1,323 257.6 2.2 -44.3 -1.5 80 96.8 
Hodgkin Lymphoma  7,400 1,323 13.2 0.1 -75.3 -3.3 30 85.9 
Non-Hodgkin 
Lymphoma 56,200 22,123 248.9 3 140.9 1.7 33 60.3 
Myeloma  14,400 10,795 272.6 1.9 252 1.9 6 31.9 
Leukemia 31,500 21,451 33 0.4 7.9 0.2 10 47.8 
Childhood 90-14) years 8,600 1,494 67.1 0.9 -70 -2.8 20 80.1 
All States 1,268,000 553,760 85.9 1.5 1.5 0.1 35 65.5 
The APC is the Annual Percent Change over the time interval. Rates used in the calculation of the APC are age 
adjusted to the 1970 U.S. Standard population. 
a. Facts and Figures, 2001. American Cancer Society. Atlanta, Georgia, 2001 
b. NCHS public use data file for the total US. Due to coding changes throughout the years: Colon excludes other 
digestive tract; Rectum includes anal canal; Liver & Intrahep includes  gallbladder & biliary tract., NOS: Lung & 
Bronchus includes trachea& pleura; Ovary includes fallopian tube; Urinary bladder includes other urinary organs; 
Kidney & Renal pelvis includes ureter: NHL and myeloma each include a small number of leukemias;  NHL 
includes a small number of ill-detinmd sites. 
c. All Sites, liver & Intrahop, Brain & Other nervous and Childhood cancers are for all races as opposed to whites. 
d. Data prior to 1973 are from Devesa, Silverman, Young, et al. Cancer Incidence and Mortality Trends Among 
Whites in the United States, 1947-48. JNCI 1987; 79:701-770 with the exception of All Sites, Liver& Intrahep, 
Brain & Other nervous and childhood cancers which come from historical Connecticut data. Data for 1973-2001 are 
from the same area used in Devena or the Connecticut registry of the SEER Program. 
e. Rates for 1950-54 are from NCI Survival Report 5 with the exception of All Sites, Oral cavity & Pharynx, Colon 
& Rectum. Non-Hodgin lymphomas and Childhood cancers which come from historical Connecticut data. Rates for 
1995-2000 are from the SEER Program with the  exception of the sites just listed which come from the Connecticut 
registry of the SEER Program. 
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Incidence  Mortality 
 
 
 
Rates age-adjusted to the 2000 US standard population 
The number next to each line segment is the Estimated Annual Percent Change (EAPC, %); * indicates p<0.05 
Figure B-1 Tobacco-related cancer incidence and mortality in the SEER 9-registries, by gender, race, and 
year of diagnosis or death (ages 20 to 84), adjusted for age and reporting delay. Lines show fit from Joinpoint 
regression 
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Incidence  Mortality 
 
 
 
Rates age adjusted to the 2000 US standard population 
The number next to each line segment is the Estimated Annual Percent Change (EAPC, %); * indicates p<0.05 
Three joinpoints were observed for screen-detectable cancer incidence in white women: EAPC1=0.08 (1975-
1982), EAPC2=4.18 (1982-1985), EAPC3=0.20 (1985-2001), and EAPC4=-3.55 (2001-2003) 
Figure B-2 Screen-detectable cancer incidence and mortality in SEER 9-registries, by gender, race, and year 
of diagnosis or death (ages 20 to 84), adjusted for age and reporting delay. Lines show fit from Joinpoint 
regression 
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Incidence  Mortality 
 
 
 
Rates age adjusted to the 2000 US standard population 
The number next to each line segment is the Estimated Annual Percent Change (EAPC, %); * indicates p<0.05 
Figure B-3 Incidence and mortality for cancer unrelated to tobacco or screening in SEER 9-registries, by 
gender, race, and year of diagnosis or death (ages 20 to 84), adjusted for age and reporting delay. Lines show 
fit from Joinpoint regression 
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Incidence        Mortality 
 
Cancer rate was age adjusted to the 2000 US standard population 
The number next to each line segment is the Estimated Annual Percent Change (EAPC, %); * indicates p<0.05 
Figure B-4 Incidence and mortality for NHL in SEER 9 registries, by gender, race, and year of diagnosis or 
death (ages 20 to 84), adjusted for age and reporting-delay. Lines show fit from Joinpoint regression 
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Table B-3 Estimates of average NHL incidence in the Pennsylvania and SEER registry by gender, race, 
and histologic subtype of the Working Formulation (WF) classification for persons diagnosed from 
1985 to 2004 at ages 20 to 84, age-adjusted to the 2000 U.S. standard population 
 White Men Black Men White Women Black Women 
Histology PA SEER PA SEER PA SEER PA SEER 
Small Lymphocytic         
   A: Small Lymphocytic 2.8 2.9 2.1 2.4 1.8 1.9 1.5 1.4 
Follicular 5.4 5.3 1.9 2.4 4.8 4.8 1.8 1.6 
   B: Follicular small 2.0 2.1 0.6 0.9 1.7 1.9 0.5 0.6 
   C: Follicular mixed 1.4 1.5 0.4 0.6 1.4 1.4 0.6 0.5 
   D: Follicular large 0.9 0.8 0.4 0.5 0.8 0.8 0.3 0.3 
       (Follicular, NOS) 1.0 0.8 0.5 0.4 0.9 0.7 0.4 0.3 
Diffuse 12.1 12.6 9.2 9.0 8.7 8.7 5.4 6.0 
   E: Diffuse small 0.8 1.0 0.5 0.5 0.3 0.4 0.1 0.3 
   F: Diffuse mixed 1.4 0.9 0.9 0.7 1.2 0.8 0.7 0.6 
   G: Diffuse large 9.9 10.8 7.8 7.9 7.2 7.5 4.5 5.1 
High-Grade 1.1 2.2 1.4 1.7 0.7 0.9 0.4 0.7 
   H: Immunoblastic 0.7 1.6 0.8 1.2 0.5 0.7 0.2 0.5 
    I: Lymphoblastic 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.1 
   J: Small noncleaved 0.2 0.5 0.4 0.4 0.1 0.1 0.1 0.1 
Peripheral T-cell 1.4 2.1 2.2 2.6 0.8 1.1 1.4 1.7 
NOS 5.1 6.0 5.3 5.8 3.5 3.5 2.9 3.0 
Rates are per 100,000 and age-adjusted to the 2000 US Std Million (19 age groups) standard. 
NOS=otherwise specified 
 
 107 
Men Women 
Box Map 
 
 
 
 
 
 
 
 
 
 
 
 
 
LISA Map 
 
       
           
           
   
 
 
Figure B-5 Box maps and LISA cluster maps for NHL incidence in the Pennsylvania registry by 
gender and county for persons diagnosed from 1985 to 2004 at ages 20 to 84, adjusted for age 
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Table B-4 Results from spatial regression analysis for assessing predictors of cancer incidence in 
Idaho among persons diagnosed from 2000 to 2004, adjusted for age 
 
 
 All sites [1] Bladder [1] 
Kidney & Renal 
Pelvis [1] 
R-square 0.396 0.243 0.394 
Independent variable β p-value β p-value β p-value 
Arsenic (ug/ml) 0.922 0.575 -0.047 0.832 0.093 0.458 
White (%)* 4.541 0.035 0.055 0.846 0.280 0.086 
Men/Women (%)* 1.988 0.388 0.077 0.804 0.113 0.518 
Population Density/Land* 0.314 0.143 -0.012 0.683 0.014 0.375 
Current Smoker (%) 6.886 0.024 0.913 0.026 0.318 0.163 
BMI<25 (%) -2.473 0.314 0.183 0.577 -0.379 0.048 
 
Liver &  
Bile Duct [1] 
Lung &  
Bronchus [2]  NHL [1] 
R-square 0.239 0.641 0.078 
Independent variable β p-value β p-value β p-value 
Arsenic (ug/ml) 0.017 0.762 0.357 0.306 0.146 0.397 
White (%)* 0.032 0.660 -0.252 0.561 -0.136 0.534 
Men/Women (%)* 0.033 0.677 0.021 0.965 0.285 0.238 
Population Density/Land* 0.005 0.519 0.012 0.778 0.008 0.732 
Current Smoker (%) 0.121 0.237 2.359 <0.001 -0.237 0.443 
BMI<25 (%) -0.048 0.570 0.086 0.866 -0.082 0.748 
[1] Ordinary least squares estimation 
[2]  Spatial lag model- Maximum likelihood estimation 
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APPENDIX C 
POWER CALCULATION FOR PROJECT#3 
We used the Risk Assessment Information System (RAIS, (United States Department of Energy, 
2006) to calculate the Excess Lifetime Cancer Risks (ELCR) for the average man and woman. 
ELCR calculations used default settings for the water ingestion rate (2 L/day), exposure time 
(0.58 hours per day), exposure frequency (350 days/year), permeability constant (0.001 cm/hr), 
oral slope factor (1.50 kg-day/mg), and dermal slope factor (3.66 kg-day/mg). ELCR calculations 
considered cancer risks from both ingested and dermal routes of exposure to inorganic arsenic 
and assumed 70 and 60 kg body weights, 1.8 and 1.6 m2 body surface areas, and 75.2 and 80.4 
year exposure durations for men and women, respectively (Table C-1). The exposure durations 
represent the life expectancies at birth for men and women in 2004 (National Center for Health 
Statistics, 2006). 
The Idaho Department of Water Resources (IDWR) provided 6,019 arsenic concentration 
measurements for approximately 1,900 ground water sources (wells and springs) distributed 
across the state of Idaho. Sampling occurred during summer months between 1990 and 2005. We 
calculated the average arsenic concentration in ground water sources from each of 23 counties 
(low risk counties) with low average arsenic concentrations (average arsenic concentration ≤2 
µg/L) and from each of five counties (high risk counties) with high average arsenic 
concentrations (average arsenic concentration ≥10 µg/L). Using 1990-2004 county-specific 
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census counts as weighting factors, we averaged the county-specific average arsenic 
concentrations to produce weighted average arsenic concentrations in water (CW) for low and 
high risk counties, 1.41 and 13.93 µg/L, respectively. 
Table C-1 shows, for men and women, the carcinogenic chronic daily intakes (ingested 
and dermal, CDI, in mg/kg-day) and ELCR at arsenic CW values of 1.41 and 13.93 µg/L. 
According to the Department of Energy RAIS, arsenic exposures in high risk Idaho counties are 
expected to increase lifetime cancer risks, relative to low risk Idaho counties, by 55.9 and 69.7 
per 100,000 men and women, respectively.  Analysis of historical U.S. census data confirmed 
significant growth in the Idaho resident population, amounting to a doubling in population size 
between 1970 and 2000, both for the state as a whole and for the five high risk counties (Figure 
C-1). According to the U.S. 2000 Census Summary File 3, 47.2 percent of residents of Idaho in 
calendar year 2000 were born in Idaho (United Stated Census Bureau). 
Table C-2 shows results from power calculations. Power calculations assume a simple 
comparison between two independent (binomial) proportions, represented by the all malignant 
cancer incidence rates expected among residents of low risk and high risk Idaho counties 
(Hintze, 2005). In analyses that compare gender-specific 15-year cancer incidence rates between 
low and high risk Idaho counties, population sizes are sufficiently large to detect (with power 
>80%) an arsenic effect (consistent with inorganic arsenic concentrations in ground water), as 
long as ≥40% of the anticipated ELCR manifests in the at-risk populations. In analyses that 
compare gender-specific 5-year cancer incidence rates between low and high risk Idaho counties, 
population sizes are sufficiently large to detect (with power >80%) an arsenic effect (consistent 
with inorganic arsenic concentrations in ground water), as long as ≥60% of the anticipated ELCR 
manifests in the at-risk populations. 
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Table C-1 Results from application of the Department of Energy risk model for inorganic arsenic 
Risk calculation Men Women 
Life expectancy (yrs) 75.2 80.4 
Body weight (kg) 70 60 
Adult surface area 1.8 1.6 
Carcinogenic CDI at CW=1.41 µg/L 4.19E-05 5.22E-05 
Carcinogenic CDI at CW=13.93 µg/L 4.12E-04 5.14E-04 
ELCR at CW=1.41 µg/L 6.33E-05 7.88E-05 
ELCR at CW=13.93 µg/L 6.23E-04 7.76E-04 
Difference (per 100,000) 55.9 69.7 
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Figure C-1 Resident population for the state of Idaho (blue line) and in five Idaho counties 
(pink line, Canyon, Owyhee, Payette, Twin Falls, and Washington counties) with average 
ground water arsenic concentrations ≥10 µg/L (Census Of Population And Housing , 
http://www.census.gov/prod/www/abs/decennial/index.htm) 
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Table C-2 Power Calculation [1] 
Power (1-β), difference between two 15-year average cancer incidence rates [2] 
  Fractional effect [4] 
Sex Incidence (per 100,000) [3] 0.20 0.30 0.40 0.50 
Men 500 [5] 0.36 0.66 0.89 0.98 
 520 0.34 0.65 0.87 0.97 
 540 0.33 0.63 0.86 0.97 
Women 360 [5] 0.64 0.94 1.00 1.00 
 370 0.63 0.93 1.00 1.00 
 380 0.62 0.92 0.99 1.00 
      
Power (1-β), difference between two 5-year average cancer incidence rates [6] 
  Fractional effect [4] 
Sex Incidence (per 100,000) [3] 0.40 0.60 0.80 1.00 
Men 500 [5] 0.48 0.82 0.97 1.00 
 520 0.47 0.80 0.96 1.00 
 540 0.46 0.79 0.96 1.00 
Women 360 [5] 0.80 0.99 1.00 1.00 
 370 0.79 0.98 1.00 1.00 
 380 0.78 0.98 1.00 1.00 
      
1.Based on two-sided Chi-square test with continuity correction and with a significance 
level of alpha=0.05 
2. Based on total at-risk population counts for the 1990-2004 15-year time period: 2,677,438 
men and 2,647,115 women in 23 low risk counties and 1,639,465 men and 1,671,457 
women in 5 high risk counties 
3.All malignant cancer incidence in the unexposed population 
4.Assumed proportion of the Excess Lifetime Cancer Risk (ELCR, estimated at 55.9 and 
69.7 per 100,000 men and women, respectively; see Table 1) manifesting in the exposed 
population (residents of high risk counties) 
5.Observed 1990-2004 age-adjusted all malignant cancer incidence rates in low risk Idaho 
counties (personal communication from the Idaho Cancer Data Registry) 
6.Based on total at-risk population counts for the 2000-2004 five-year time period: 934,663 
men and 924,388 women in 23 low risk counties and 629,358 men and 637,956 women in 5 
high risk counties 
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